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ABSTRACT

Protein Production in the Milk of Genetically Engineered Animals

by

Katherine M. Bates, Master of Science
Utah State University, 1998

Major Professor: Dr. John D. Morrey
Department: Animal, Dairy and Veterinary Science

There are numerous proteins that have potential uses in commercial and sc ientific
applications that are not utilized to their full potential. This is partly because it is not
economically feasible to isolate some of these proteins from their natural sources or to
produce them using bacterial fermentation methods. The purpose of this research was to
target recombinant protein expression to the manm1ary glands of genetically engi neered or
transgenic animals. Foreign protein expression has been achieved in the mammary glands
of rabbits, sheep, cows, and swine. By using a strong mammary gland promoter and
signal peptide fused to the protein, it was hypothesized at the beginning of the study that
the two proteins of this study would be secreted into the milk.
To test this approach for protein production, expression vectors for two different
plant proteins were made. The proteins targeted for expression were thaumatin and
brazzein, proteins that have sweetener or flavor altering properties. The regulatory
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portion of the expression vector used exons and introns from the milk 13-casei n gene.
Four and a halfkilobases of the 5' region of the bovine 13-casein gene was isolated, which
contained the promoter sequence and other regulatory sequences for gene expression in
mammary tissue . A size of2.2 kilobases of the 3' region of the J3-casein gene contained
further regulatory sequences as well as a polyadenylation signal. The gene sequence for
the protein was mod ified by using codons commonly used for casein and was generated
using sy nthetic oligonucleotides. Additionally, the signal peptide from the alpha S-1
casein gene was used to transport the protein into the mammary milk vesicle. The DNA
expression vectors were subsequently injected into murine and caprine embryos for the
production of transgenic animals. Transgenic mice and a goat were identified that
contained the thaumatin transgene. Preliminary analysis of mouse milk by capillary gel
electrophoresis indicated the express ion of thaumatin protein. This protein expression
system is intended to utilize large dairy animals as bioreactors for efficient, non-toxic
protein production with a view to being appl ied to different proteins as the technology
advances.
(118 pages)
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INTRODUCTION
The long-term goal of this research was to target foreign protein expression to the
milk of genetically engineered livestock animals in order to obtain large-scale protein
production of potentially valuable proteins.
The hypothesis is that high levels of functional protein can be produced if the
sequence for the foreign protein is placed under the regulatory control of an inducible
mammary gland-specific promoter that has been shown to induce gene expression during
lactation. By fusing the protein with a secretory signal peptide, the proteolytic enzymes of
mammary gland cells can cleave exactly at the carboxy-terminal end of the signal peptide.
The functional , native protein is secreted into the milk -producing vesicles of the mammary
epithelial cells. The mammary glands in transgenic animals have been shown to be
effective for protein production using various combinations of mammary-specific
promoters and proteins (4, 32-34). For this study, an expression vector was made which
was composed of a mammary gland-specific promoter, regulatory region, and signal
peptide sequence such that the gene of interest could be inserted into the expression vector.
The vectors were then micro-injected into pronuclear-staged embryos that were implanted
into surrogate dams and carried to term. Those offspring that had incorporated the
trans gene should express the foreign protein in the milk. The protein can then be harvested
from the milk.
Two proteins that have flavor-enhancing/sweetener properties were used to test the
expression vector. The first protein was thaumatin, which is a sweet-tasting protein from
the fruit of a West African perennial herb Thaumatococcus Daniellii Benth. Over the years
thaumatin has been shown to have multiple applications that are economically important.
However, it does not naturally occur in high enough quantities to meet the current market.
Various recombinant methods have been, and continue to be, used to attempt to produce
recombinant thaumatin to meet the market demands. These methods to date have proven
unsuccessful, because they either do not yield functional protein or they do not produce a
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large enough thaumatin yield to make the production economically feasible. The second
protein was brazzein, a sweetener protein found in plants. The gene was isolated from a
wild African plant Pentadiplandra brazzeana Baillon (36) . Although there is not currently a
market for brazzein, it has properties that suggest it is the most superior protein sweetener
known (24 ). It is 2000 times sweeter than sucrose, more water-soluble than any other
protein sweetener, is thermostable, and possesses a sucrose-like taste.
The goal of this project was to develop the gene expression vectors containing the
genes of interest, generate transgenic mice, and develop assays that could be used to detect
the proteins.
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LITERATURE REVIEW
Previous work in generating transgenic animals
The first transgenic animal was made in 1980. By injecting pBR322 plasmid
containing portions of the herpes simplex and SV40 viruses into the pronucleus of an early
mouse embryo, mice were generated that contained the injected plasmid in their genome
(12).
Since the first transgenic mice, the use of transgenic animals has been incorporated
in a variety of fields, such as for models of human diseases. By using these transgenic
mouse models, the disease traits and mechanisms can be better studied in a living system.
Another application is using transgenic animals as bioreactors to produce recombinant
products by achieving expression in the mammary gland or the blood (16), which is the
effort of this research.
Incorporation of the transgene and regulation of gene expression
The DNA sequence to be targeted to the host genome is purified and microinjected
into the pronuclei of single-cell fertilized oocytes. The transgene integrates into the genome
of the embryo by recombination. If the foreign DNA, or transgene, is integrated into
germline cells of the animal, the transgene will be inherited by the transgenic progeny
through Mendelian genetics (16).
The genetic expression vector is designed such that the gene of interest will be
easily recognized and regulated by the host cellular mechanisms. The DNA sequence
consists of regulatory regions that are required for the tissue-specific recognition of the
foreign DNA. Mammary gland-specific transcription factors bind to the regulatory
sequences of the promoter, which synthesizes the corresponding RNA. Inducible
transcription factors are synthesized at specific times during cell cycling and development,
in specific tissues, and play a role in the control of transcription (20). These promoter-
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associated factors enhance or suppress the efficiency of the RNA polymerase/transcription
complex to initiate and transcribe the DNA sequence into messenger RNA (mRNA). The
enzyme responsible, RNA polymerase, continues along the sequence in a 5' to 3' direction
until it reaches and recognizes the polyadenylation signal - AAT AAA. This results in the
subsequent addition of a polyadenylic (poly A) tail to the 3' end and cessation of
transcription. The mRNA includes both the regulatory intronic and coding exonic regions.
To remove the introns , the mRNA is processed or spliced. The processed mRNA, which
now has a S'cap and a 3' poly A tail, is then transported out of the nucleus to the cytoplasm,
where it is translated into the corresponding amino acid residues.
The mammary gland proteins found in milk need to be translocated into milk
secretory vesicles. This is facilitated by a secretory signal peptide that is flush with the first
residue of the protein to be secreted (28). The signal peptide is recognized by factors
associated with the membrane of the secretory vesicle and these membrane-associated
factors cause the peptide to be transported through the membrane of the secretory vesicle.
As it is passing through the membrane, the signal peptide is cleaved away from the
remainder of the protein at the signal peptides' carboxy terminal end. Consequently only
the remaining protein sequence is secreted in the milk (20).
Previous work in targeting expression to the mammary tissue
Transgenic protein expression in the milk has been achieved by other investigators.
Some examples of such proteins are human tissue plasminogen activator (6), human
growth factor (33), and whey acidic protein (18) . Such research has shown that
heterologous mammary-specific promoters can be used to express transgenic proteins in the
milk of transgenic animals as illustrated below.
Whey acidic protein (WAP) is a milk protein that is unique to the rodent family.
Transgenic swine and sheep were generated using the gene coding for the murine W AP.
This resulted in theWAP being expressed at a high level of 3% (0.9 g per liter) of the total
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milk proteins (18). Expression of this rodent mammary-specific gene in swine and sheep
demonstrates that milk or mammary gland-specific promoters could still be functional! y
recognized in a heterologous species. It also demonstrates that a murine protein could be
expressed at high levels in the milk livestock animals.
The utility of theWAP promoter provided the opportunity to express human
proteins in the milk of livestock animals. The eDNA of human protein C (hPC), utilizing
the first exon of W AP gene, was expressed at a high concentration of 1 giL in swine. In
addition, the biological activity was comparable to that of hPC obtained from human
plasma (32).
Selection of promoter and regulatory elements
The protein concentration of milk is 32 giL. The caseins, of which there are four
types, alpha-s I, alpha-s2, beta and kappa, comprise 76-86% of the milk proteins. Each of
the casein genes has been utilized in a transgenic system. The milk protein genes contain
short conserved sequences in their 5' flanking regions which contain the binding sites for
the tissue-specific transcription factors (16) . The casein genes are expressed in the
mammary glands of the animals during the late gestation and lactation periods under the
influence of hormones.
Of the four caseins, beta-casein is the second most prevalent at 9 giL. A
comparison between the promoters of the beta-casein of different species show that the
DNA sequences are conserved. This is indicative of the biological importance of betacasein as a component of milk. These casein promoters are useful for milk expression of
proteins. For example, a 3-kb portion of the beta-casein promoter region was successfully
used to achieve expression of a portion of the caprine kappa-casein gene in mice (13) .

In

vitro expression of the bovine beta-casein promoter has been induced in the HC 11
mammary epithelial cell line, in the presence of insulin, glucocorticoid, and prolactin (2).
The beta-casein promoter region was linked to the CAT reporter gene and expression levels
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were measured. As a negative control, the SV40 promoter was fused with the CAT
reporter gene and no expression was seen (2) . These hormonal conditions resemble those
seen during lactation.
Selection of thaumatin protein for study
Thaumatococcus daniellii Benth is a perennial herb which grows predominantly in

the West African countries and other humid regions on the African continent. Its fruit is
known to be very sweet, and as a result, is used both as a fruit delicacy and a food additive
by the indigenous people. T. daniellii grows naturally and is also cultivated and farmed
due to its economic value. As well as the fruit being used for food , the remaining portions
of the plant have a variety of other uses that make it practical for production in these
countries (1).
Characteristics of thaumatin
There are five known thaumatin proteins. The predominant proteins are thaumatin I
and II. They are both 207 amino acids long and they only differ by 5 amino acid residue
changes ( 10). Thaumatin II is considered to have the strongest role in fl avor altering
properties and therefore has been the protein of choice for recombinant DNA production.
The protein has eight disulfide bonds, which would presumably account for the heat
stability observed. After boiling the thaumatin protein for 1 hour, once it has cooled, it
regains its sweetness (21). In the plant, thaumatin is secreted as a pre-pro-thaumatin with
22 amino acids on theN-terminus and 6 amino acids on the C-terminus. These sequences
are cleaved as the protein is compartmentalized.
Sweetener properties and uses of
thaumatin
Thaumatin is 3000 times sweeter than sucrose and has also been shown to enhance
the sweet taste of food s and other non-nutritive sweeteners such as saccharin (11) . It is
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TABLE I. Applications of thaumatin sweetener protein (I I )
Amount (ppm)
Effect
Product
0.2 - 0.5

enhances fl avor and masks bitterness

pet food , anjmal feed

0.5 - !.0

modi fies fl avor and enhances aroma

coffee, artificial fla vor

30- 200

prolongs flavor and intensifies sweetness

gum and candy

50- ISO

masks bitterness and contributes sweetness

oral pharmaceuticals

best to use thaumatjn for its ability to enhance taste and fl avor due to the delay in perception
of sweetness and an after-taste of licorice (II ). Table I summarizes the different
applications of the thaumatin protein.
Thaumatin has been successfully used in the feed of weaned piglets to cause them
to eat more feed so that they would gain weight faster. Adding thaumatin to the water of
weaned pigs at I part per million (ppm, l!g/g) caused the pigs to drink more water and eat
more feed , which resulted in more rapid weight gain (table 2). It has also been tried in
other livestock animal feed applications and has been shown to increase the palatability in
both cat and dog foods. For example, the eating preference of cats for thaumatin-treated
feed was 82% as compared to 18% for untreated food (14).

TABLE 2. Effect of I ppm thaumatin on the feed or water intake and performance of
2-week-weaned piglets (14)
Control
Treatment
Thaumatin
Improvement
Initial average weight (kg)
3.45
3.68
Final average weight (kg)

10.70

12.64

+ 1.69 kg

Average daily gain (g)

207

256

+ 12.4%

Average feed intake (kg)

9.36

11.5

+ 2. 14 kg

Feed conversion ratio

!.29

1.29

Water intake (L) 6 days

2.9

4.06

Trial duration (days)

35

35

+40 %
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Commerce
Proteins are advantageous as sweeteners because they are generally not toxk and
have low caloric content. However, most protein sweeteners are found in exotic plants,
and therefore the production can be limited. If they cannot be obtained in suffic ient
quantities from the native source, they could either be chemically synthesized or made by
recombinant DNA technology. Presently there is not widespread use of thaumatin because
there is not a large enough natural supply of the protein and due to political and economic
factors the production costs are high. From a political standpoint, the countries that grow

T. daniellii have an unstable political history. This results in some reluctance on the part of
clients to purchase thaumatin due to a perceived unstable supply (5). Attempts have been
made to grow T. daniellii in greenhouses in the United Kingdom but no fruit was produced
(2 1). Thaumatin has an existing market for use in animal feeds, due to its taste-enhancing
properties. However, the high cost of extracting the low level of protein from the fruit and
exporting it limit its full commercial potential.
In an attempt to solve the supply problems associated with obtaining the thaumatin
protein, extensive research has been undertaken to produce the protein using recombinant
DNA technology. An initial attempt to produce recombinant thaurnatin (r-thaumatin) in

Eschericia coli (E. coli) resulted in low-level thaumatin that could only be deteted usi ng
sensitive radiolabeled methods (10). In addition to only obtaining low levels of protein in
E. coli, the protein was also not processed properly in the cell and therefore was not

functional to exhibit sweet taste. Presumably one of the problems encountered with this
effort was that the native signal sequence, that allowed secretion of the functional protein,
was not recognized in bacteria. Therefore, the thaumatin protein was probably not
processed or secreted properly. Bacillus subtilis and Streptomyces bividans naturally have
high levels of enzyme secretion ( 13, 17). Better yields were obtained when using B.

subtilis or S. bividans than were seen with E. coli , but the levels were not high enough for
commercialization.
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The most promising results were seen usi ng the yeast Saccharomyces cereviseae
(2 1, 38). For this effort, a synthetic gene sequence was used that contained codons that
were commonly used in yeast systems. The secreted thaumatin was not sweet unless the
extracted protein was chemically denatured and then renatured into the functionally sweet
form ( 19). Investigators eventual ly produced sweet thaumatin by fusing the invertase
signal peptide sequence to the thaumatin protein sequence. The resulting protein possessed
sweetness presumably because it was processed into the tertiary structure properly and was
secreted into the growth medium. Under direction of the invertase signal sequence, a yield
of 300 mg!L, from protein secreted into the growth medium, was obtained. Although this
was a high yield, it did not reach the break-even point for commercialization (35). Table 3
summarizes some of the attempts to produce thaumatin by recombinant technology.
These microbial production methods have not yet proven successful for large-scale
commercial production of the functional thaumatin protein, because the market for
thaumatin is dependent on a high yield and low cost.

Host

TABLE 3. Recombinant thaumatin ex12ression attem12ts (11)
Gene Description
Activity

Yield

E. coli

pre- and pro-gene

not functional

B. subtilis

pre-gene

not functional

low (IS)

S. lividans

pre-gene

not functional

low (11)
low (10)

low (10)

K. lactis

pre- and pro-gene

not functional

A. orysae

pre- and pro-gene

not functional

low (11)

S. tuberosum

pre- and pro-gene

functionally sweet

low (21)

S. cerevisiae

mature gene

not functional, but wasrefolded ex

high (19)

vivo to a sweet form
signal peptide linked
with mature gene

functionally sweet

high (35)
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Selection of brazzein protein for study
Brazzein, like thaumatin, is also a sweetener of plant origin. It was discovered in a
wi ld African plant Pentadiplandra brazzeana Baillon (24) . Brazzein is the most superior
sweetener protein known. It is 2000-fold sweeter than sucrose and is more water soluble
than any other protein sweetener. It is thermostable because it contains eight cysteines.
The electophysiological taste profile ofbrazzein is si ntilar to sucrose (24). The sweetness
of brazzein is immediate and short lasting unlike thaumatin. Functionally sweet brazzein
was obtained using nticrobial host systems albeit at low levels (personal communication,
Goran Hellekant, University of Wisconsin) . This functional production in bacteria increase
the likelihood that brazzein secreted in the ntilk will retain the desirable sweetness
properties of the native brazzein.

Characteristic

TABLE 4. Comparison of thaumatin and brazzein (23 ,27)
Thaumatin ll
Brazzein

Origin

T daniellii

P. brazzeana

Sweetness'

3,000

2,000
54 antino acid residues

Protein size

207 antino acid residues

Molecular mass

22,293 Da

6,473 Da

Flavor altering property

flavor and aroma enhancer

sucrose-like sweet taste

Water soluble

yes

yes

Heat stability

regains sweetness after boiling

sweetness retained after 4 hr

for I hr when cooled

at80"C

' Compared to 2% aqueous sucrose

II
EXPERIMENTAL DESIGN
This Experimental Design section outlines the strategy and justification for the three
objectives stated below without elucidating the details of the methods. An Experimental
Methods section, following this Experimental Design section , describes the details of the
methods.
I. Construct an expression vector containing genes of interest designed to target protein
expression to the mammary gland and secretion of the proteins into the milk.
2. Generate a line of transgenic founder animals.
3. Develop an assay to detect and quantify the fl avor/sweetener proteins.
Objective 1: Construction of expression vector
The expression vector seen in figure I was designed to target expression of the
flavor/sweetener proteins, thaumatin and brazzein, to the mammary gland. One major
component of the vector was a 13-casein promoter anticipated to cause tissue-specific
expression of the gene in mammary glands. Another component of the vector was a
synthetic oligonucleotide sequence for the genes of the flavor and sweetener proteins
targeted for expression. The synthetic oligonucleotides also included the code for the
signal peptide required to transport the protein into the vesicles of the mammary glands so
that it would be secreted in the milk. The amino acid sequence for the signal peptide from
alpha SJ-casein was used (accession #M33123). Alpha SJ-casein is the predominant milk
protein at I 0 giL (31) and has previously been used successfully to cause secretion of
proteins into the milk (29). The third component was the 3' portion of the 13-casein gene
that contained a polyadenylation signal (poly A) from the 13-casein gene. In addition to the
essential promoter and poly A regions, the 3' and 5' segments of the 13-casein gene
included several k.ilobases of intronic and exonic regions. It was hypothesized that greater
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5 'Beta-casein sequence

D

Synthetic gene
3' Beta-casein sequence

mwMl

I

5' 13-casein regul atory sequence: Contained the promoter and enhancer regions for gene

express ion in the mammary gland tissue, this included 13-casein intron I, ex on 1, and a
portion of exon 2, a transcription start codon and the sequence for the first three amino acid
residues of the secretory signal peptide.

W2l Synthetic genes were designed for both thaumatin and brazzein, they
consisted of the following: 1. Signal peptide sequence from alpha S !-casein( 17)
2. Synthetic sequence for fl avor proteins
3. Two stop codons at 3' end

81 3' 13-casein regulatory sequence: Contained a portion of 13-casein ex on 7 as well as
intron 7, exon 8, intron 8, exon 9 and the poly-adenylation signal.
FIG. I. Components of expression vector.
efficiency of expression would be achieved when a high proportion of the native coding
sequences were included in the vector (6).
The sequence for the bovine 13-casein gene was obtained from the Genbank data
base, accession #Xl4711. Primers were designed, using this sequence, that were
comple mentary to portions of the 5' and 3' regulatory regions of the bovine 13-casein gene.
The 5 ' and 3' DNAs were then obtained by performing the polymerase chain reaction
(PCR) on bovine white blood cells. The various regulatory regions and pertinent
restriction enzyme sites for the 5' promoter region and the 3' polyadenylation region are
shown in figures 2 and 3, respectively. Rather than show the entire sequence, the regions
have been truncated and the length indicated by the base number at the beginning and end
of each row. Exons were identified by underlining. In the 5' 13-casein segment, the TATA
box was italicized and underlined. The restriction enzyme site, Ppuml, was convenient
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because it only appeared once in the 5' portion, and it was at the beg inning of the signal
peptide. The synthetic gene was designed such that when ligated to the 5' 13-casein region
using the Ppuml site, the sequence for the signal peptide would be in the correct
translational reading frame.
The polyadenylation signal , in the 3' region of the 13-casein gene, was connoted by
the sequence TT ATT, which was underlined in figure 3. The restriction enzyme sites,
Kpnl and BamHI, were incorporated into the ends of the 3'13-casein sequence during PCR
using primers designed specifically for this purpose.

A at//
GACGTCATTAGGAAAT UPSTREAM REGULATORY REGION
46

-----+---------+

ATTTCAAACCAC
-------+---1664
TAAAGTTTGGTG

CTGCAGTAATCCTTTA

AAAATTAGCATGCCATTAAATACTATATATA AACAACCACAAAATCAGATCATTATCC8I
1665 -----+---------+------ - --+-- - -- - ---+-- - - - ----+---------+-1724
TTTTAATCGTACGGTAATTTATGAXATA TAT TTGTTGGTGTTTTAGTCTAGTAATAGGTA
TCAGCTCCTCCTTCACTTCTTGTCCTCTACTTTGGAAAAAAGGTAAGAATCTCAGATATA
1725 -----+---------+---------+---------+----- - - --+ - -----1784
AGTCGAGGAGGAAGTGAAGAACAGGAGATGAAACCTTTTTTCCATTCTTAGAGTCTATAT
ATTTCATTGT
1785 -----+---TAAAGTAACA

INTRON #I ( 1767-3701 )

AGGGAAGTAATTCTACT
-- -+ - - - ------+--3644
TCCCTTCATTAAGATGA

TAAATAAGAAAATAGATTGACAAGTAATACACTATTT CCTCATCTTCCCATTCCCA~

3645 ---- - +---- -- - - - +- - - ---- --+ - - - - -----+----- -- --+- - -------+--3706
ATTTATT CTT TTAT C TAA CTGT T CATTATGTGATAAAGGAG TAGAAGGG TAAGGGTC~

Ppuml
GAGAGCCATGAAGGTCC
3707 ---+ - --- - - - --+- - - 3723
CTCTCGGTACTTCCAGG
LRAMKYL
SIGNAL PEPTIDE RESIDUES

(1-4)

FIG. 2. Features of the 5' 13-casein portion of the expression vector.
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Kpnl
TGGGTACCAGGATAAAATCCACCCC

EXON#7(8028-8525) CCTGTCCGGGGA

---------+---------+------b£CCATGGTCCTATTTTAGGTGGGG

-

-

-

-

-

-- --+- - -- 8510
GGACAGGCCCCT

CCCTTCCCTATTATTGTAAGTCTAAATTTACTAACTGTGCCTGTTTAACTTCTGATGTTT
8511 ---------+------- --+- ---- ----+----- - ---+--- ---- --+-------QGGAAGGGATAATAACATTCAGATTTAAATGATTGACACGGACAAATTGAAGACTACAAA

8570

GTATGATATTCGA
INTRON #7 (8526-9126)
TTTTATTTTATTAT
8571 -- - ------+---------+---------+---------+---------+---------+ 9110
CATACTATAAGCT
AAAATAAAATAATA
TTTTTTTATTTTTAAGGTCTAAGAGGATTTCAbAGTG8ATGCCCCCTCCTCACTTTTGGT
91 11 -- --- ---- +---- -----+ -- --- - ---+---------+ - --------+----- -- --+9170
AAAAAAATAAAAATTCCAGATTCTCCTAAAGTTTCACTTACGGGGGAGGAGTGAAAACCA
AAGCTTTAGGATAT
INTRON #8 (9169-9898)
TCTATGTTTGTTCTCTA
- -------+ -- -------+9890
9171 - ------ - -+-- -- --TTCGAAATCCTATA
AGATACAAACAAGAGAT
TTCCACAGAbTTGACTGCGACTGG EXON#9(9899 - 10221) 8ACATATCAA8ATA
9891 ---------+---------+---- - - - - - - - - ----- -- -+ ---- ----- 1013 0
AAGGTGTCTTAACTGACGCTGACC
TTGTATAGTTTTAT
TGTATbAAAATAATTTCTGGAATTGTGATTATTATTTCTTTAAGAATCTATTTCCTAACC
10131 ---------+---------+---------+---------+---------+---- - ---10190
ACATATTTTTATT8AAGACCTT8ACACTAbTAATAAAGAbATTCTTAGATAAAGGATTGG
AGTCATTTCAATAAATTAATCCTTAGGCATATTTAAGTTTTCTTGTCTTTATTATATTTT
10191 --- - -----+-- -- ---- -+ ----- --- -+-------- - +---------+-- --- ----10250
TCAGTAbAGTTATTT8ATTAGG8ATCCGTATAAATTCAAAAGAACAGAAATAATATAAAA
TTTTAATGAAATTGGTCTCTTTATTGTTAACTTAAATTTATCTTTGATGTTAAAAAGAGC
10251 -- - - -- --- +- - -- -- ---+---------+ ----- - --- +-- - -- ----+- --------+ 10310
AAAATTACTTTAACCAGAGAAATAACAATTGAATTTAAATAGAAACTACAATTTTTCTCG
BamHI
TGTGGAAAATTAAAATTGGATCCAATTCCC
103 11 -- -------+- ---- - - - -+-- --- ----ACACCTTTTAATTTTAACCTAGGTTAAGGG

FIG. 3. Features of the 3'B-casein portion of the expression vector.
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Design of sy nthetic genes
The native sequences from plants for both thaumatin (9) and brazzein ( 13) were
known . Synthetic oligonucleotides were desi gned to code for the protein sequences to
generate the genes. The DNA sequences found in the plant genes of thaumatin and
brazzein were not used due to the frequency that some codons were used in plants as
compared to mammals. There were one to four codons that could potentially code for each
of the twenty amino acids. Different codons could be used with varying frequencies
depending on the type of organism that might be analyzed. Investigators have shown that
levels of thaumatin protein can be dramatically improved by using the codons that were
commonly used normally in the organism, which was yeast in their case ( 19). The
common codon usage of milk protein genes and plant genes of the family Marantaceae, to
which Thaumatococcus belongs, was determined usi ng Wisconsin GCG Sequence
Analysis Software Package (Genetics Computer Inc.) . To illustrate this concept, the
analysis of codon frequencies of milk proteins for the amino acid leuci ne was compared to
the frequencies of codons used for plant proteins (table 5). TTA, the codon that was not
used in the milk proteins, was used frequently in plants. Therefore, if the native sequence
that contained the codon TT A were used, the expression system would probably not have
sufficient tRNA' s capable of recognizing the codon and translating it into the corresponding
amino acid, which in this case, was leucine. Therefore, using the published sequence of
thaumatin (Genebank accession #AI5660), and the sequence contained in the patent (36)
for brazzein, the nucleic acid sequences were modified in the synthetic genes as compared
to the native plant genes. The gene was designed to contain the common codons used in
the mammary gland genes. The codons used in the native plant thaumatin or brazzein
genes were preserved unless they were used with frequencies less than 20% in mammary
gland genes.
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TABLES. Common codon

freguenc~

of leucine

Plant 12rotein codon usage

Mammalian milk 12rotein codon usage

CTG

0.03

CTG

0.47

TTG

0.28

TTG

0.11

CTC

0.00

CTC

0.22

CTA

0.19

CTA

0.02

CTT

0.17

CTT

0.18

TTA

0.33

TfA

0.00

The remainder (residues 3 through 15) of the alpha S !-casein secretory signal
peptide sequence on the 5' end of the flavor/sweetener gene up to the Ppuml restriction site
(figure 2) was coded by synthetic sequence. The nucleic acid sequence for the signal
peptide was modified slightly due to the construction of a Ppuml site for cloning purposes,
but the amino acid sequence was preserved. A comparison between the wild-type nucleic
acid sequence for alphaS !-casein signal peptide and the sequence that was used in the
vector is shown in figure 4.
Synthetic: "2

Ct£[ ate Ct£[ !:!_CC tgc ctg gtg geE. ,UtE. gee Ct£[ gC£

Bovine B-casein:

etc ate ctt gee tgc ctg gtg get ctg gee ctt gca

L
L

L
L

T
A

c
c

L
L

v
v

v

A
A

L

A
A

L
L

A
A

Bovine a.Sl-casein: etc ate ctt ace tgt ctt gtg get gtt get ctt gee

L

L T

c

L

V

A

V

A

L

A

I : underline indicates differences when compared to B-casein
2: italic indicated differences when compared to alphaS !-casein
FIG. 4 . Comparison ofa.-sl-casein with P-casein and the synthetic sequence used.
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Two stop codons followed by a Sal! restricti on enzyme site for thaumatin and
brazzein gene sequences were positioned on the 3' end of the synthetic sequence as can be
seen in fi gures 5 and 6, respecti vely. Once the desired sequence of the genes was known,
synthetic oligonucleotides were made, either by National Biosciences, Inc. or the USU
Biotechnology Service Laboratory.
Ppuml
gcacggaqgtcctgatcctgacctgcctggtggccgtcgccctggccgccacctttgaga

---------+--------- +-- -------+---------+----- ----+---------+

60

cgtgcc~actaggactggacggaccaccggcagcgggaccggcggtggaaactct

V

L I L T C LV AVA LA
SIGNAL PEPTIDE RESIDUES 3-15

AT

FE

I-

tcgtgaacagatgcagctataccgtgtgggctgccgctagcaaaggcgatgccgccctgg

61

-- -------+---- ---- -+---------+---------+---------+---------+

120
agcacttgtctacgtcgatatggcacacccgacggcgatcgtttccgctacggcgggacc
V N R C S Y T V W A A A S K G D A A L D -

Kpnl
atgccggaggcagacagctgaactccggcgagagctggaccatcaacgtggagccc~

121

-------- - +---------+------ ---+ ---------+- ------ --+------ ---+ 180
tacggcctcc gtctgt cgacttgag gccgctc tcgacctggt agttg cacctcggg~

A

G

G

R

Q

L

N

S

G

E

S

W T

I

N

V

E

P

G

T -

£Qaagggcggcaagatctgggccagaaccgactgctattttgacgatagcggaagaggca

181

---------+---------+-------- -+- ------- -+- -- ---- --+- ----- ---+ 240
ggttc ccgccgttctagacccggtcttggctgacgataaaactgctatcgccttctccgt

K

G

G

K

I

W A

R

T

D

C

Y

F

D

D

S

G

R

G

I -

tctgccggac cggcgact gtggcggactgctgcagtgcaagagatttggcagacctcct a

241

--- ----- -+-- ---- ---+----- ----+-- -------+------ - - -+- - --- - ---+ 300
agacggcctggcc g ct g acaccgcctgacgacgtcacgttctctaaac cgtctggaggat

C

R

T G
Ddel

D

C

G

G

L

L

Q

C

K

R

F

G

R

P

P

T -

ccactctgg~t ttagcctgaacc agtatgg caaggactatatcgatatcagca aca

301

-- - ---- --+ - --------+---------+---------+---------+---------+ 360
ggtgagacc~aaatcggacttggtcataccgttcctgatatagctatagtcgttgt

T

L

A

E

F

S

L

N

Q

Y

G

K

D

Y

I

D

I

S

N

I -

tcaagggctttaatgtgcctatggactttagccctactaccagaggctgcagaggcgtga

361

--- ----- -+---------+---------+---------+---------+------- --+ 42 0
agttcccgaaattacacggat a cctgaaatcgggatgatggtctccgacgtctccgc act

K

G

F

N

V

P

M D

F

S

P

T

T

FIG. 5. Sequence of the synthetic thaumatin construct.

R

G

C

R

G

V

R -
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gatgcgctgccgacatcgtcggccagtgccctgccaagctgaaggcccctggaggcggct

421

- --------+---------+---------+---------+---------+---------+ 480
ctacgcgacggctgtagcagccggtcacgggacggttcgacttccggggacctccgccga
C A A D I V G Q C P A K L K A P G G G C Spel
gcaatgacgcctgcaccgtgtttcag~gagtattgctgcaccactggcaagtgcg

481

---------+- --- -----+---------+---------+---------+ --- ------+ 540
cgttactgcggacgtggcacaaagtc ~ctcataacgacgtggtgaccgttcacgc

N

D

A

C

T

V

F

Q

T

S

E

Y

C

C

T

T

G

K

C

G -

gccctaccgagtatagcagattttttaagagactgtgccctgacgcctttagctatgtgc
541

----- -- --+- --- ---- -+- ----- --- +----- - ---+- ---- ----+ -- ------ -+ 600
cgggatggctcatatcgtctaaaaaattctctgacacgggactgcggaaatcgatacacg
P T E Y S R F F K R L C P D A F S Y V L tggacaagcctaccaccgt gacctgccctggcagcagcaactatagagtgacct tttgcc

601

---------+---------+---------+---------+---------+---------+

660
acctgttcggatggtggcactggacgggaccgtcgtcgttgatatctcactggaaaacgg
D K P T T V T C P G S S N Y R V T F C P Sal/
ctac cgc ctagtag~gctgcg

661

-- -------+---------+------ 686
gatggcggatcatc~cgacgc

T

A

FIG. 5. Continued .

Ppuml
gctcgg~tgatcctcacctgcctggtcgccgtggctcttgccgacaaatgcaaga

1

---------+-------- -+---------+--------- +------ ---+---------+

60

cgagcc~actaggagtggacggaccagcggcaccgagaacggctgtttacgttct

V

L

I

L T C L V A V A L A D
SIGNAL PEPTIDE RESIDUES 3-15

K

C

K

K -

aagtgtacgagaattatcctgtgagcaagtgccagctggccaaccagtgtaattacgact

61

---------+---------+---------+---------+---------+----- --- -+

120
ttcacatgctcttaataggacactcgttcacggtcgaccggttggtcacattaatgctga
V Y E N Y P V S K C Q L A N Q C N Y D C -

gcaaactggacaagcacgccagatccggggaatgcttctatgacgaaaagcggaacctgc
121

---------+----- - - --+------- -- +----- -- --+-- ---- ---+ --- ----- -+ 180
cgtttgacctgttcgtgcggtctaggc cc cttacgaagatac tgcttttcgccttggacg
K L D K H A R S G E C F Y D E K R N L Q Sal/
agtgtattggcgattattgcggctagtaa~gcggc

181 --- ---- --+- -- ------+-------- - +---------+- 221
tcacataaccgctaataacgccgatca tt~cgccgc

C

I

G

D

Y

C

G

FIG. 6. Sequence of the synthetic brazzein construct.
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A general outline of the order in which the different components were cloned into
the plasmid backbone was shown in figure 7. Agel and Aatll were used to li gate the S'Bcasein region into the pGFP-Cl vector (figure 7, first and second image). This particular
vector was used because there was no Ppurnl site in the vector, wh ich was necessary for
subsequent manipulations. When the synthetic genes were ligated into the vector (figure 7,
fourth image), the Agel and Ppurnl sites were used and the 1.5 kb sequence between
Ppuml and Agel was lost from the vector sequence. The 3' B-casein region was ligated into
the vector in a similar manner using the BamHl and Kpnl restriction enzyme sites (figure 7,
third image).

Construction of the synthetic genes
The oligonucleotides that constituted both brazzein and thaumatin were generated
synthetically. Due to the size of the thaumatin gene, as compared to the brazzein synthetic
gene, the gene had to be divided into four pieces to make the synthetic thaumatin gene. As
diagrammed in figure 8, eight separate thaumatin oligonucleotides were synthesized and
cloned into plasmids as four separate groups (second line of figure 8). These four groups
were then ligated together as shown in the third line of figure 8. To achieve orderly
ligation, restriction enzyme sites were designed into the gene so that once the individual
clones were obtained they could be ligated together to form the final synthetic gene product
of 686 bp (fourth line, figure 8). The middle enzyme, Ddel, was a non-palindromic
enzyme; therefore, the ligation involving that restriction enzyme site could only be achieved
in one orientation.
Brazzein was only 220 bp long by comparison, so only two oligonucleotides were used to
generate the brazzein gene. Therefore, the intermediate steps required to make the
thaumatin gene were not necessary for the construction of the brazzein synthetic gene
(figure 9). The details of these steps were described completely in the Methods section.
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Age I (601)

Aatll

Age I (601)

Aat II (224)

FIG. 7. Design of the genetic expression vector.
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c

D
d

r

Hybridization and extension of complementary oligonucleotides
Ppum I

Aa

Kpn I

=l=l=--~

Kpnl

Bb

Odel

Ode I

Cc

Spel

Spel

Dd

Sail

+=-=-=t- +=-=t= +=-=t=

Amplified by PCR and PCR product cloned into pUC-Smal
Ppum I Aa
Kpn I
Kpn I
Bb Ode I Ode I Cc Spe I Spe I Dd Sail
puc:j:::===::fpuC puc:j:l====+IIpUC puc:j:::===::::j:puc puc:j:::===::::j:puc

Individual cloned segments ligated together

Ppum

I

Kpn

I

Ode

I

Spe

I

Sail

puc :t::::::::::::+:::::::::::f::::::::::::f::::::::::~~·· puc
FIG. 8. Construction of the thaumatin synthetic gene.

Ppuml

Sail

Hybridization and extension of complementary oligonucleotides
Ppum I

Sail

Amplified by PCR and cloned into pUC-Smal

Ppuml

Sail

pUC-r--------------------~uc

FIG. 9. Construction of the brazzein synthetic gene.
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I. Expression vector was microinjected into pronucleus and integrated into the host
genome

PF

Aa{/1
!AlA

Ex I

c::::J

lnl ATG
~

5' B-Casein

3' B-Casei n

Kpnl
TAGTJ

Signal Peptide
EZZl

Bm$,1 Mlul

MEx7 ln 7- Ex8 ln8

-

Ex9 ~

Syn thetic gene

pGFP-CI

2. In the mammary tissue, the DNA sequence was transcribed into mRNA. Sequences
flanking the promoter and polyA were not transcribed.

Ex I

In I

Ex7 ln7 Ex8 In8 Ex9

~~UAAA

3. mRNA was processed, and the regulatory introns were spliced out.

Ex I

Ex7

Ex8

Ex9

4. Translation of processed mRNA into the corresponding amino acids.

5. Signal peptide was cleaved during transport across the secretory vesicle membrane

FIG. 10. Anticipated transgenic mRNA and protein processing in vivo.
Figure I 0 illustrates the expected cell processing of gene products once the
expression vector had been incorporated into the host genome. The products of the
expression vector would undergo a series of modifications that were cell-cycle dependent
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that would ultimately result in only the fl avor/sweetener proteins, not the fused signal
peptides, being present in the mammary milk secretary vesicle and secreted into the milk.
Objective 2: Generation of transgenic lines to test the expression vector
Mice were used as the model to test the expression vector. The synthetic gene was
injected into the pronuclei of one-cell stage embryos. Mice were super-ovulated and
sacrificed and the reproductive tracts collected to obtain the embryos . The surviv ing
embryos after microinjection were transferred into recipient mice that were pseudoimpregnated with a vasectomized male mouse (27). The offspring were screened (using
PCR and Southern blot hybridization) 3 weeks after birth to detect whether they had
incorporated the trans gene. The founder animals, shown to have the trans gene, were then
used to establis h further generations of transgenic mice. This effort was accomplished by a
team of people in Drs. John Morrey' s and Kenneth White's laboratories at Utah State
University . My involvement was to screen the resulting mice for the transgenes.
Objective 3: Detection of protein in the milk of the transgenic mice
An enzyme-linked irnmunosorbant assay (ELISA) was developed by using crude
native thaumatin plant protein as a standard (Sigma Chemical Co. , St. Louis, MO). The
assay was developed to detect and quantify the levels of thaumatin and brazzein proteins.
Antibodies were generated against the thaumatin and brazzein proteins in both goats and
rabbits and the serum was isolated for use in the assay . A goat capture antibody specific
for one of the proteins was bound to the ELISA plate. The standards or milk samples,
potentially containing the transgenic proteins, were sandwiched between the goat antibody
and a rabbit antibody specific to the protein. The detection system made use of an antirabbit antibody conjugated to horse radish peroxidase. When the substrate for the enzyme
was added, a color change corresponding to the concentration of the antigen was observed.
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Additionally, a mouse milk sample from a putative transgenic mouse was analyzed
using capi llary electrophoresis which separated the proteins according to the charge-tomass ratio. Migration towards the negative electrode depended on the charge density of the
molecule with small, highly positive charged species eluting first, followed by larger, less
charged species. The new transgenic proteins should be observed in the milk by this
method.
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EXPERIMENTAL METHODS
Objective I: Constructi on of expression vector

Cloning B-casein regions into pGFP-CI
Isolating B-casein DNA fragments
PCR (26) was performed on bovine blood cell s using primers designed from the
sequence found in the Genbank data base, accession #Xl4711. The resulting PCR
products were fractionated on a I% Seaplaque GTG argarose gel (FMC Bioproducts,
Rockland, ME). The agarose gel was stained by soaking in a 0.5 mg/ml ethidium bromide
(Sigma Chemical Co. , St. Louis, MO) solution that allowed visualization of the DNA when
the gel was viewed under UV light. DNA bands of the predicted sizes of the 5' and 3' Bcasein DNA were seen at 4,600 bp and 2,220 bp, respectively, when the correct PCR
products were obtained. The previous development and optimization of the PCR was done
by Javier Alcazerra and Charoensri Thonabulsombat in Drs. John Morrey 's and Ken
White' s laboratories (Utah State University).
A method was developed to overcome problems encountered with cloning PCR
products. PCR products are notoriously difficult to clone into vectors. For example, one
problem seen with the use ofTaq DNA polymerase is the addition of adenosines to the end
of each strand that it synthesizes. Various methods have been developed by others to
overcome this cloning difficulty, such as l ) using a cloning vector with a thymidine
overhang and, 2) using primers with restriction enzyme sites designed into them (7).
However, known improvements of PCR cloning were not successful to clone the PCR
products of this study.
The following method was successful in cloning the PCR products for this
experiment. The product was first digested with proteinase K (8) to presumably remove
the residual Tag polymerase and any other proteins that could be interfering with
subsequent manipulations. The PCR samples were digested with 50 Jlg/ml proteinase K
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(Sigma Chemical Co., St. Louis, MO), in I X proteinase K buffer (0.5 % SDS, 5 mM
EDTA, 1 mM Tris) at 37°C for 30 rrun . The proteinase K was then heat-inactivated at 65°C
for 20 min so that the enzymes used in the next reactions were not destroyed by any
res idual proteinase K that was sti ll active. Next, the samples were purified by
phenol:chloroform extraction and ethanol precipitation (PC/EtOH)(3).
Cloning of 5' 13-casein DNA into pGFP-CI
After suspending the treated PCR product of the 5' 13-casein region in TE buffer (I 0

mM Tris, I mM EDT A pH 8.0), it was then cloned into the vector pGFP-C I (Ciontech,
Palo Alto, CA). This particular vector was not used because of the presence of green
fluorescing protein gene; rather, it was used because of convenient restriction enzyme sites
present in the plasrrud. During the cloning process, the green fluorescent protein gene was
lost from the plasrrud. The cloning was achieved by digesting both the vector pGFP-C I
and the purified 5' 13-casein PCR product with the restriction enzymes Aatii and Agel (New
England Biolabs, Beverly, MA . All enzymes were from New England Biolabs unless
otherw ise stated.). They were digested with Aatll in IX NEBuffer#4 at 37°C for
approximately 2 hours, purified by PC!EtOH, and digested with Agel with IX
NEBuffer#l at 37°C for 2 hours. After being suspended in TE buffer, the DNA
concentration was measured on both the pGFP-CJ that had been cut with Aatll and Agel
and the 5' 13-casein product that had been cut with Aatll and Agel. The 4,478 bp 5' 13casein fragment was ligated into the 4,728 bp pGFP-CJ using a one-to-one molar ratio of
insert to plasmid, a total DNA concentration of 50 ng/].tl, IX T4 DNA polymerase buffer,
and I unit (U) ofT4 DNA polymerase. The ligation rruxture was incubated for at least 8
hours at I6°C. An amount of 5 ng of the ligation reaction was transformed into DHS-alpha
E. coli transformation-competent cells using a Biorad Gene PulserTh1 and the protocol
accompanying the instrument's instructions (Bio-Rad, Hercules, CA.). The transformation
reaction was then plated out onto Luria·-Bertani (LB) (I% bacto-tryptone, 0.5 % bacto-yeast
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extract, I% NaCI) agar plates containing 30 J.Lglml kanamycin (Sigma Chemical Co. , St.
Louis, MO). Kanamycin antibi otic was used because pGFP-Cl contains a kanamycinresistance gene. The presence of this gene ensured that only those colonies that contained
the plasmid survived in the presence of kanamycin. The plates were incubated overnight at

3TC. The following day, single bacterial colonies were picked from the plates under
sterile conditions and inoculated in 2 ml of LB media that contained 30 J.Lglml of
kanamycin . After incubation of individually picked colonies in LB media at 37oc for 12 16 hours, the DNA was isolated using an alkaline lysis miniprep method (30) which
purified the circularized plasmid away from the bacterial genome.
To screen the DNA obtained from the colonies for plasmids that contained the S'Bcasein DNA, the uncut plasmids were fractionated on a I % Seakem LE gel (FMC
Bioproducts, Rockland, ME). Those plasmids that migrated differently on the gel were
plasmids that possibly contained an insert. Each putative clone was subjected to restricti on
enzyme analysis and fractionated on I% Seakem LE agarose to diagnose which clone had
an insert in the correct orientation (see Experimental Design, figure 7). A correct clone
would result in the followin g size DNA fragments when cut with the restriction enzymes as
indicated; Aatii and Agel: 4.4 kb & 4.7 kb, Spel: 7.3 kb & 1.8 kb. The clone that
exhibited the correct diagnostic bands was then sequenced by the USU Biotechnology
Laboratory. Once the correct clone had been identified, it was then used as the backbone
into which the remaining DNA fragments were ligated. The correct clone identified at this
step, that consisted of S' B-casein DNA and pGFP-CI , was referred to throughout the text
as p5' B-cas.
Cloning 3' B-casein DNA into pUC-19
The transformation of ligation products of gel-purified fragments with p5 ' B-cas was
inefficiently low, if not nonexistent, i.e., no correctly transformed bacteria were obtained.
For this reason, it was necessary to use a circuitous approach to clone the remaining
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segments into p5 ' 13-cas. This was accompli shed by first cloning the PCR products into a
simple plasmid, pUC19, and then subcloning the fragment from pUC19 into p5 ' 13-cas .
The 3'13-casein proteinase K-treated PCR product obtained in step #I was first
cloned into the vector pUC 19 using blunt end ligation, which does not involve sequencespecific overhanging sticky ends. The PCR product was blunt-ended and phosphorylated
using the fo ll owing reaction conditions: 1 X T4 DNA polymerase buffer, l mM ATP, 0.8
mM dNTP 's, 50 !J.g/ml BSA, 20 U polynucleotide kinase, and 6 U ofT4 DNA

polymerase. The reaction was incubated for 30 min at 37°C and heat inactivated at 75°C for
10 min. After heat inactivation the DNA was purified by PC/EtOH and then suspended in
TE buffer.
The pUC was prepared for blunt-ended ligation by digestion with Smal restriction
enzyme that created a blunt end. The digestion reaction was incubated with Smal enzyme
and NEBuffer#2 at 25°C. A small aliquot of approximately 10 ng was removed for
analysis by gel electrophoresis to confirm that digestion of the plasmid did occur. When
fractionated on a I% LE agarose gel (FMC Bioproducts, Rockland, ME), a band was
visible that corresponded to the predicted size of 2,686 bp. The remaining digested pUC
plasmid was purified by PC/EtOH and suspended in TE buffer in preparation for the
ligation reaction.
A ligation reaction was prepared that contained the blunt-end, phosphorylated 3' 13casein PCR product and pUC-Smal at equimolar ratio of ends, I U T4 DNA ligase, IX
ATP-free ligase buffer (Stratagene, La Jolla, CA), and 50 !J.M ATP. After incubation for a
minimum of 8 hours at 25°C, 5 ng of the reaction was transformed as described above
(Experimental Methods, step #I). Ampicillin was the antibiotic used to select for the pUCcontaining bacterial colonies. In the previous experiment, kanamycin was the antibiotic
used because the plasmid pGFP-Cl was used. By using the multiple cloning site in
pUC19, blue-white selection (3) of Lac operon function was used. The media and agar
contained 50 !J.g/rnl ampicillin (Sigma Chemical Co. , St. Louis, MO) to select for bacterial
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colonies containing the pUC vector; and the agar plates contained 20 ).lg/ml X-gal (S igma
Chemical Co. , St. Louis, MO) and 0. 1 mM JPTG (Sigma Chemical Co., St. Louis, MO)
to select for an insert in the multiple c loning site.
Single white colonies were picked under sterile conditions and inoculated at 37°C
with shaking for 12-18 hours in 2 ml of LB media that contained 50 ).lg/ml of ampicillin.
The DNA was isolated by alkaline lysis and suspended in TE buffer, and the uncut
plasmids were fractionated on a I% Seakem LE gel. Those plasmids that migrated
differe ntly when compared to a pUC plasmid control, were plasmids that possibly
contained an insert. The correct clone was identified by separate restriction enzyme
digestions using Kpnl and Hindlll. The predicted sizes depended on the orientation of the
fragment within the plasmid as noted: orientation I - Kpnl : 2,224 & 2,682 bp, Hindiii:
I, 174 & 3,732 bp or orientation 2 - Kpnl: 4,902 & 4 bp, Hindlll: I , 190 & 3,716 bp (the
small fragments would not be visible on a l % gel). The putative correct clones were
contirmed by sequencing the complete insert as performed by the USU Biotechnology
Laboratory .
Cloning 3' B-casein into p5 ' B-cas construct
Both p5 ' B-cas and pUC-3 ' B-casein were digested with BarnHI and Kpnl using a
double restriction enzyme digestion in which both enzymes were used in one reaction at a
maximum amount of 2.5% total volume per enzyme to avoid having star activity. The
reaction also contained NEBuffer for BamHI and IX bovine serum albumin (BSA). This
would result in DNA fragments of the following sizes being produced for p5'B-cas: 9, 185
& II bp, and for pUC-3' B-casein: 2,696 bp (pUC) & 2,210 bp (3' B-casein). The

samples were purified by PC/EtOH after incubation with restriction enzymes at 37°C for l2 hours. The plasmid and insert-fragments were not separated from each other before the
ligation. The DNA samples were suspended in TE and the concentration of DNA measured
by depositing l ).11 of each DNA sample onto ethidium bromide plates (0.5 ).lg/ml ethidium
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bromide, I % Seakem agarose) and comparing the degree of fluorescence of the samples to
the fluorescence of DNA standards of known concentrations. The ligation reaction was
designed to have a 3: I molar ratio of ends of 3' B-casein DNA to p5'B-cas. The li gation
reaction did not have more than 50 11g of DNA per 111 of total reaction volume. The
appropri ate amounts of DNA were incubated along with I U ofT4 DNA ligase and IX
NEBuffer at l6°C for a minimum of 8 hours. An amount of 5 ng of the ligation reaction
was transformed by electroporation using XLI-Blue Epicurian Coli®ElectroporationCompetent Cells (Stratagene, La Jolla, CA) that had a transformation efficiency of 5 x I 09
colony forming units per 11g of DNA (CFU/!lg) as compared to home-made cells which
typically had a transformation efficiency of I x 108 CFU/11g. This higher efficiency
increased the likelihood of one of the transformants containing the desired clone. A volume
of 50 111 of the transformation reaction was plated onto LB agar plates that contained
kanamycin at a concentration of 30 !lg/ml. Only a colony that contained the p5' B-cas
plasmid could survive on the kanamycin media; therefore, the possible clones that could be
present on the plates were I) p5'B-cas that had re-ligated with the II bp fragment, 2) p5 'Bcas +pUC, and 3) p5'B-cas + 3'B-casein. Any aberrant ligation products involving pUC
(not kanamycinresistant) without p5'B-cas would not result in transformed colonies. The
most efficient way to identify the desired clone ofp5'B-cas + 3'!3-casein was by using a
radiolabeled 3'!3-casein probe that would bind to the DNA in those clones that contained the
3' B-casein DNA region. After incubation of the plates overnight at 37°C, the colonies were
transferred and bound onto a nitrocellulose membrane (Schleicher & Schuell, Keene, NH)
(30) in preparation for analysis by colony hybridization.
The DNA template used for the random labeling reaction to make the probe was
generated from the pUC-3'B-casein clone. It was digested with BamHI and EcoRI using
NEBuffer for EcoRI, and 5 X BSA at 37°C for at least I hour. This generated two
fragments: the 3'B-casein DNA segment along with 16 bp of the pUC plasmid (2,236 bp)
and the remai nder of the pUC plasmid (2,670 bp). The DNA bands were fractionated on a
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1% Seaplaque GTG agarose gel (FMC Bioproducts, Rockland , ME) and the 2,236 bp
fragment was exc ised from the gel. The DNA was isolated from the gel slice using 13agarase digestion (protocol with product insert, New England BioLabs, Beverly, MA).
The 13-agarase cleaved the complex carbohydrates into polysaccharides that were no longer
capable of forming a gel-matrix. The protocol for accomplishing this was as follows: the
gel sl ice was weighed, placed in a microcentrifuge tube and incubated in one tenth volume
13-agarase buffer at 70°C for 10 min. It was placed in a 40°C water bath and the gel slice
was allowed to cool to that temperature which took approximately 2 minutes. 13-agarase
enzyme ( I U) was added for every 200 mg of gel, and the reaction was incubated at 40°C
for 1-2 hours with regular vortexing. Once the reaction appeared liquid, 3M sodium acetate
solution (pH 5.2) (Mallinckrodt Baker, Inc., Paris, KY) was added to a final concentration
of 0.3 mM and placed on ice for I 0 min. This caused agarose to precipitate out of solution.
Centrifugation at 12,000 rpm for I 5 min pelleted the precipitated agarose. The supernatant
containing the DNA was transferred to a fresh tube. The DNA was precipitated using
ethanol precipitation (EtOH) and suspended in TE buffer. DNA concentration was
measured on a DNA fluorometer according to the instructions given with the instrument
(Hoefer Scientific Instruments, San Francisco, CA). An amount of 25 ng of template DNA
was heated to boiling temperature for 5 min and quenched on ice. The following reaction
components were added to make a total volume of 20 Ill: 2 J.11 reaction mixture (Boeringer
Mannheim, Indianapolis, IN), 0.5 mM of each dNTP (Pharmacia Biotech Inc.,
Piscataway, NJ) , 5 Ill
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P dCTP 3000 Cilmmol (ICN Biochemicals, Costa Mesa, CA) and

I Ill KJenow polymerase (Boeringer Mannheim, Indianapolis, IN). The reaction was
incubated at 37°C for 30 min and stopped by adding I J.11 of 0.5 M EDT A. The efficiency
of the reaction in terms of percent incorporation was determined by removing and
dispensing I Ill of the reaction on a DE81 Whatman filter (Baxter, McGaw Park, IL). The
DE81 filter was then subjected to several washing steps (23) which removed unincorporated nucleotides . Using the ratio of the " before" and "after" radioactive counts the
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reaction efficiency was calculated. A reaction efficiency of 25 % was sufficient for colony
hybridization.
Before the filters containing the DNA could be incubated with the probe, they were
floated DNA-side up on a solution of 6X SSC for 5 min, completely submerged in the 6X
SSC for 5 min , and then sealed in a "seal-a-meal" bag with prehybridization solution (5X
Denhardts, 5X SSC, I% SDS , and I 00 Jlglml denatured sal mon sperm DNA, Sigma
Chemical Co. , St. Loui s, MO) at a volume of I ml per cm2 of membrane. The bag was
incubated at 68°C for 30 min, and then the prehybridization solution was drained and fresh
hybridization solution added which contained the probe. This was incubated at 68 °C for at
least 8 hours. Filters were then washed according to medium stringency conditions (30).
After wrapping the filters in cellophane, Kodak XAR film (VWR Scientific, Salt Lake City,
UT) was exposed to the filters for I day. After developing the film , potential positive
clones were identified and matched to the original agar plates. A number of putative
colonies were inoculated individually in 2 ml LB media with 30 Jlg/rnl kanamycin and
incubated overnight at 37°C. The DNA was then isolated by alkaline lysis mini prep, and
the correct clone was identified. A clone that had only the 3' 8-casein DNA within p5'8cas
in the correct orientation was identified by restriction enzyme analysis. The reaction
conditions for each enzyme reaction are given in parentheses as follows: Hindill (IX
NEBuffer#2, 37°C} : 9.9 kb & 1.2 kb, BamHI & Kpnl (IX NEBuffer for BamHI, 5X
BSA, 37°C}: 2.3 kb & 8.8 kb, Sail (IX NEBuffer for Sail, 5X BSA, 37°C}: 11.1 kb and
Xbal (NEBuffer #2 , 37°C}: 3.4 kb, 4.5 kb & 3.2 kb.
The clone that contained DNA fragments of 5'8-casein and 3' 8-casein in the pGFP
vector was referred to throughout the text as p5 ' 3' 8-cas.
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Generating separate segments of
sy ntheti c genes
Synthesis of indi vidual oligonucleotides
Individual oligonucleotides as indicated in figure 8 (Experimental Design) were
synthesized by National Biosciences Inc. (Plymouth , MN). Their standard operating
procedure was modified for synthesis of long oligonucleotides by deprotecting the
oligonucleotides at 60°C overnight as opposed to 80°C for several hours. National
Biosciences Inc. also did not do any polyacrylamide gel electrophoresis (PAGE)
purification of the oligonucleotides. These modifications were necessary because PCR was
used to ampli fy the oligonucleotides, and it was noticed that when these alterations in the
protocol were not performed, there was a high freq uency of random error in the PCR
products. The desiccated oligonucleotides were received and suspended in double-distilled
water to a concentration of I Jlg/Jll.
Hybridization and polymerization of
complementary oligonucleotides
The oligonucleotide pairs were designed to have approximately IS overlapping basepairs.
The design for the two oligonucleotides used to make the brazzein synthetic gene along
with the primers is shown in figure 11 . The sequences of the 4 individual segments, as
well as the PCR primer designs used, were shown for the synthetic thaumatin gene in
figure 12.
Braz up: 11 7 bases in length
gctcggaggtcctgat ------aaccagtg taattacg
1

------- --+---- -----+---------+- - --- -- - -+--- -- ----+--------- 221
ggtcacattaatgctgacgt- - ---agctgcgccgc
Braz low: I 18 bases in length

Overlapping region: 14 bases
Hybridi zed brazzein (Braz up and Braz low): 221 bp long
Upper primer: 5' GCACGGAGGTCCTGATCCT 3' 19 bases long
Lower primer: 5' CGCCGCGTCGACTT ACT A 3' 18 bases long
FIG 11 . Design of brazzein oligonucleotides and PCR primers.
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Thaumatin A:
O ligo A: 98 bases in length
gcacgg---------taccgtgtgggctgccgct

----- ----+ ---------+-------- -+----- ----+- --------+------- --+

1

188

cacacccgacggcgatcg tttc--- -- -- ---ggttcccg

Oligo a-: 105 bases in length

Overlapping region: 15 bases
Hybridized segment A (A+ and a-): 188 bp long
Upper primer(A+): 5' GCACGGAGGTCCTGATCCT 3' 19 bases long
Lower primer(A-): 5' GGCCTTGGTACCGGGCTCCA 3' 20 bases long

Thaumatin B:
Oligo B+: 72 bases in length
gagcccggta ---- --ttttgacgatagcggaagaggcatc

171

---------+---------+---------+----- ----+---------+--------

323

tcgccttctccgtaga------c tcaaatcggac
Oligo b-: 96 bases in length

Overlapping region: 15 bases
Hybridized segment B (B+ and b-): 153 bp long
Upper primer (B+): 5' GAGCCCGGTACCAAGGG 3' 17 bases long
Lower primer(B-): 5' CAGGCTAAACTCAGCCAG 3' 18 bases long

Thaumatin C:
Oligo C+ : 11 5 bases in length
ctctggctga -- -----ccagaggctgcagaggcgt

305

--- ------+------- --+------ ---+---------+---------+--------

515

ctccgacgt ctccgcactctacg--- -- gtctgatcactc
Oligo c-: 113 bases in length

Overlapping region : 16 bases
Hybridized segment C (C+ and c-):
Upper primer (C+): 5' CTCTGGCTGAGTTT AGCCT 3' 19 bases long
Lower primer (C-): 5' CTCACTAGTCTGAAACACG 3' 19 bases long

Thaumatin D:
Oligo D+: I 03 bases in length
gtgtttcaga-----gacgcctttagctatgtgc

511

------ ---+---------+---------+---------+---------+--------ggaaatcgatacacgacctgttcg----ccagctgcgacgc
Oligo d-: 101 bases in length

Overlapping region : 15 bases
Hybridized segment D (D+ and d-):
Upper primer (D+): 5 ' GTGTTTCAGACTAGTGAG 3' 18 bases long
Lower primer (D-): 5' CGCAGCGTCGACCTACTAGGC 3' 21 bases long
FIG. 12. Design of thaumatin oligonucleotide segments and PCR primers
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The overlapping regions we re hybridized together and the single-stranded portions
were filled in by T4 DNA polymerase to generate the four double-stranded segments used
to make the thaumatin gene (figure 8 overview). One J.l.g of each oligonucleotide was
suspended in I X Sequenase buffer (USB, Cleveland, OH) to give a final volume of 19 J.l.l.
The reaction mixture was incubated at 70°C for 10 min to denature any oligonucleotides that
could have abberently hybridized while in solution. The hybridization of the overlapping
region then occurred while the reaction was cooled slowly to 37°C. The single-stranded
portion of the hybridized oligonucleotides was filled in by the addition of I J.l.l (10 U) of
Sequenase Version 1.0 enzyme (USB, Cleveland, OH) and 2 Jll of a2 .5 mM dNTP mix to
give a final reaction volume of 22 J.l.l. The reaction occurred at 37°C for 30 min. The
reaction was heat-inactivated by incubation at 70°C for 10 min . The DNA was then
purified by PC/EtOH and the pellet suspended in 10 Jll of TE buffer. DNA concentration
was measured using an agarose ethidium bromide plate as previously described.
Amplification using PCR
It was necessary to ampli fy each fragment by PCR in order to generate sufficient
DNA concentrations for subsequent manipulations (figure 8, overview). The primers for
PCR used for each segment were indicated in figure II . The PCR primers were
synthesized by the USU Biotechnology Laboratory. The PCR was performed using the
following reaction conditions: 50 ng of DNA template, 10 J.l.M of each primer, 5 U PFU
enzyme (Stratagene, Lalolla, CA), 50 Jlglml BSA (Miles Inc. , Kankakee, IL), 25 J.l.M each
dNTP, dH20 to a final volume of 50 J.l.l and IX buffer (Invitrogen Corp., San Diego, CA).
For each fragment, five identical reactions were run that differed only by the buffer used.
The optimization buffers varied in pH and MgCI 2 concentrations. The therrnocycler
(Perkin Elmer Cetus, Norwalk, CO) was programmed with the following cycling
conditions: I cycle for 7 minutes at 95°C and 30 cycles consisting of the following
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temperatures: denaturation for 30 sec at 95°C, annealing for 30 sec at 58°C, and extension
for 40 sec at 72°C. A volume of 5 Jll of the reaction product was run on a 2.5% Seaplaque
GTG gel to detect the predicted PCR product sizes that were indicated at the bottoms of
figures II and 12.
Preparation of the PCR product for cloning
into pUC plasmid
The remaining 45 Jll of PCR product was treated with proteinase K, which
improved the cloning efficiency. Concentrations of 50 jlg/ml of proteinase K and IX
proteinase K buffer were used and the reaction was incubated for 30 min at 37°C. It was
then heat-inactivated for 20 min at 65°C. The samples were purified by PC/EtOH and the
pellet was suspended in TE buffer. The DNA ends were phosphorylated and blunt-ended
using the following reaction conditions: IX T4 DNA polymerase buffer, I mM ATP, 0.8
mM dNTP's, BSA to 50 jlg/ml, 20 U polynucleotide kinase, and 6 U ofT4 DNA

polymerase. The reaction was incubated for 30 min at 37°C and heat-inactivated at 75 °C for
10 min. The reactions were purified by PC/EtOH and the pellet was suspended in TE
buffer.
The pUC plasmid was prepared for blunt-ended ligation as described in a previous
section of Experimental Methods.
Ligation and screening of ligation products
Each PCR-generated fragment of thaumatin and the synthetic sequence for brazzein
was ligated into pUC-Smai using a I0: l molar ratio of insert to plasmid. Ligation reactions
components were ATP-free ligation buffer, 50 JlM ATP, and 2U T4 DNA ligase. The final
DNA concentrations were between 40-50 ng/jll. The reactions were incubated at 25°C
overnight.
A volume of I Jll of each ligation reaction was used to transform bacterial cells that
were prepared for heat-shock transformation (30). After transformation , the culture was
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pl ated onto LB agar plates containing 50 J.tg/ml ampicillin , IPTG, and X-gal, which
a llowed for blue-white selection of pl asmids contain ing an insert. The plates were
incubated overnight at 37°C. A volume of 2 ml LB broth, containing 50 J.tg/ml ampicillin,
was inocul ated with single white colonies and incubated overnight at 37°C in a shaker.
DNA was obtained using the alkaline lysis method. The potential clones were then
screened by a double-digestion with Bam.HI and EcoRl restriction enzymes in the presence
of NEBuffer for EcoRl and I 00 J.tg/ml BSA. The reactions were incubated at 37°C for 2
hours and then run on a 2.5% Seaplaque GTG gel. Correct putative clones had bands at
the followin g sizes: thaumatin A: 209 bp, thaumatin B: 174 bp thaumatin C: 233 bp and
thaumatin D: 210bp.
The identify of the clones was confirmed by DNA sequencing in both directions.
Alkaline lysis mini prep DNA was extracted with phenol:chloroforrn once, chloroform
twice, and then ethanol precipitated. They were then sequenced by the USU
Biotechnology Laboratory with the primers used previously to amplify the fragments.

Combining thaumatin segments
Joining segments A&B and C&D
The relationship between the four thaumatin fragments is shown in figure 13. The
different frag ments/segments, that were cloned into the vector pUC, were referred to as A,

Ppur I

Aa 188bp

Kpr I
Bb 153bp

DT

Cc 212bp

Overlapping region between Aa and Bb = 18bp
Overlapping region between Bb and Cc = 20bp
Overlapping region between Cc and Dd = 18bp

FIG. 13. Relationship of thaumatin segments with each other.

Dd 189bp

r
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B, C & D. Both A and B were digested with Kpnl in the presence of NEBuffer for Kpni
and IX BSA for a minimum of I hour at 37°C. At thi s point, the thaumatin fragments were
still attached to pUC at one end , but both had a Kpni free overhanging end. Once the Kpni
enzyme digestion was completed, both the A and B reactions were purified by PC!EtOH.
After suspension in TE buffer and measurement of the DNA concentration , A and B were
ligated together using an equal DNA ratio with T4 DNA ligase and !X T4 DNA ligase
buffer at !6°C overnight. The ligation product was then cleaned up once again by
PC!EtOH. In preparation for PCR which was done to amplify the AB product, the pUCAB was linearized using an enzyme, Xbal, that was only present in the pUC plasmid and
not in either of the thaumatin segments. The enzyme reaction conditions were as follows:
NEBuffer#2, IX BSA, and Xbai enzyme.
After incubation at 37°C for several hours and purification by PC!EtOH, PCR was
performed on the ligation products using PCR primers A+ and B- (figure !! ) under the
same reaction and cycling conditions that were used previously to amplify the individual
fragments as described on page 35.
The generation of C and D ligated together was performed in the same way as the
generation of A and B ligated together in the above description, except that Spel restriction
enzyme was used instead of Kpnl, and primers C+ and D- were used for the PCR.
The PCR products containing AB and CD fragments were fractionated on a large,
50 em long, sequencing gel apparatus (Bio-rad, Hercules, CA) that would allow good
separation of bands from aberrant products such as AA, BB , CC, or DD. A !0%
polyacrylamide gel (PAGE) was prepared (30). The bands at 323 bp for AB and 383 bp
for CD were excised from the gel. The gel slice was placed in a microcentrifuge tube,
crushed, and subsequently isolated by incubation in PAGE elution buffer (0.5 M
ammonium acetate, 10 mM magnesium acetate, 1 mM EDT A (pH 8.0) and 0.1% SDS)
overnight at 37°C while shaking. The reaction was centrifuged at 12,000 rpm for 1 min to
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pellet the polyacrylamide. The supernatant was transferred to a separate tube and ethanol
precipitated to remove the DNA from the gel. The DNA pellet was dried and suspended in
TE buffer, and the concentration was measured using ethidium bromide plates.
Combining thaumatin AB and thaumatin CD
The PCR products AB and CD that were purified from the PAGE were digested
with the restriction enzyme Ode! using NEBuffer #4 at 37°C for 1-2 hours and then
purified by PC/EtOH. A ligation was then done using the same conditions as described in
the previous section when A,B and C,D were being joined. However, in this instance
there was no pUC plasmid present because the AB and CD PCR products were not
subcloned into pUCI9 but were purified from the polyacrylamide gel. PCR was then
performed on the ligation mixture with the primers A+ and D-. As indicated above, the
same reaction and cycling conditions that were used in the original amplification of the
synthetic fragments were utilized. This PCR reaction yielded a PCR product of 686 bp.
The PCR product was subcloned into pUC-Smal as described in B .5 of the methods
section. A volume of I 111 of the ligation was used for transformation by heat-shock
treatment and plated on LB/X-gal/IPTG/ampicillin pl ates to screen the products of the
ligation reaction . Putative plasmids that contained an insert were selected using blue/white
selection and incubated in LB media that contained 50 ~-Lg/rnl ampicillin. After the DNA
was isolated from the inoculum, putative clones that contained the complete thaumatin
synthetic gene were identified by double restriction enzyme digestion with BamHI and
EcoRJ in the presence of NEBuffer for EcoRJ and I X BSA for 2 hours at 37°C. Those
clones that had a band in the region of 686 bp when fractionated on a 2.5 % agarose gel
were sequenced by the USU Biotechnology Laboratory. Sequencing was important to
ensure that the entire sequence was exactly as designed and that no random errors had
occurred as a result of using PCR to amplify the different ligated segments.
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Inserting flavor or sweetener genes into
p5'3'11cas construct
Preparation and ligation of plasmid and insert
As outlined in figure 7, the synthetic genes were ligated into p5 ' 3' 13cas at the
restriction enzyme sites Sail and Ppuml. The p5 ' 3'13cas plasmid and brazzein-pUC or
thaumatin-pUC were digested with Ppuml , the reaction was incubated with NEBuffer #4
at 37°C for 2 hours, and then digested with Sail using NEBuffer for Sail and IX BSA at
37°C for several hours after purification by PC!EtOH. A small amount of each reaction
was fractionated by agarose gel electrophoresis to check that the complete digestion had
occurred before the reactions were prepared for ligation. The samples of the plasmid
(p5 ' 3'13cas) that had been cut with Ppuml and Sa!I, as well as the thaumatin and brazzein
genes that had been cut with Ppuml and Sail, were purified by PC!EtOH and then
suspended in TE buffer. The DNA concentrations were measured. A ligation reaction was
carried out using a 3: I equimolar ratio of ends of insert (flavor/sweetener genes) to plasmid
(p5'3'13cas), IX T4 DNA ligase buffer and 4U T4 DNA ligase at l6°C for a minimum of8
hours.
Screening ligation of flavor genes into p5 '3'13cas
To identify a correct clone as seen in figure 7, fourth panel, bacteria containing the
ligation reaction were transformed using Stratagene XLI-Blue Epicurian Coli®
Electroporation Competent cells and the Bio-rad Gene Pulser apparatus. After incubation
of the electroporation reaction at 37°C for I hour, the bacterial culture was then diluted I :5
and spread on LB agar plates that contained 30 !lg/ml kanamycin and were incubated
overnight at 3rC. The reaction was diluted to obtain a concentration of colonies on the
surface of the plates in which individual clones could be identified. As previously
described in Experimental Methods, the colonies on the agar plates were transferred onto
nitrocellulose filters, and the plasmids were screened using a 32P labeled probe specific for
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either brazzein or thaumatin. The templ ate for the probe was obtained by double digestion
of thaumatin-pUC or brazzein-pUC with BarnHl and EcoRI using NEBuffer for EcoRI and
I X BSA at 3TC for 2-3 hours. The reactions were fractionated on a 2.5 % Seaplaque

GTG agarose gel, and the bands at 696 bp and 231 bp for thaumatin and brazzein ,
respecti vely, were excised and purified by B-agarase digestion as described previously in
Experimental Methods. The radiolabeled probes were prepared using the following
reaction conditions: 25 ng DNA template that had been boiled and then quenched on ice, 2
~I reaction mixture, 0.5 mM of each dNTP, 5 ~I ·" p dCTP 3000 Cilmmol, I ~I K.lenow

polymerase and dH 20 up to 20 ~1. The reaction was incubated at 37°C for 30 min and
stopped by adding I

~I

of 0.5 M EDT A. After calculating the specific activity of the probe ,

it was boiled to denature the DNA and added to the filters. The filters along with the probe
were incubated overnight at 68°C. The unbound or weakly nonspecific-bound probe was
washed from the filter using the conditions described previously in Experimental Methods.
Correct putative clones were identified after exposure of the X-ray film to washed filters
and subsequent development. These colonies were picked, the DNA isolated by alkaline
lysis mini prep, and then screened using a digest with Ppuml and then with Sal! using the
reaction conditions described previously in Experimental Methods. Those clones that
contained the correct insert liberated bands corresponding to the size of thaumatin and
brazzein in addition to bands of predictable sizes of the plasmid. The orientation of these
clones was confirmed with further restriction mapping. Several putative clones were then
sequenced by the USU Biotechnology Laboratory. They were sequenced across the
junctions between 5' 3 'll-casein and flavor genes to confirm that they were in the correct
translational reading frame.
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Objective 2: Generation of transgenic lines to test the expression vector

Preparation of expression vector
for microinjection
The expression vector containing the genes of interest had to be removed from the
pGFP-Cl plasmid backbone in which it was cloned to prepare it for microinjection into
pronuclear-staged embryos. The thaumatin expression vector was digested with Aatii
using NEBuffer #4 at 37°C for several hours, purified by PC/EtOH, and then digested with
Mlui enzyme using NEBuffer#3 at 37°C for several hours. The reaction was then
fractionated on a I% Seaplague GTG gel and the band at 5.8 kb was excised. The DNA
was isolated from the gel using B-agarase digestion as previously described in the protocol
supplied with the enzyme (New England BioLabs, Beverly, MAJ. This was followed by a
further purification step using an Elutip chromatography column (Schleicher and Schuell,
Keene, NH). The DNA obtained from the B-agarose reaction was suspended in a low salt
butler (0.2 M NaCl , 20 mM Tris HCL, 1.0 mM EDTA (pH 7.4)), instead ofTE buffer, in
preparation for the Elutip procedure. The protocol given in the instructions for the Elutip
column was followed. After ethanol precipitation the pellet was suspended in microinjection buffer (5 mM Tris pH 7.2, I mM EDTA pH 8.0) at a concentration of 2 ng/Jll.
When performing restriction enzyme digestions on the brazzein expression vector
(Brazzein-5'3'8-casein), an extra Mlul site, other than what had been predicted, was
identified within the pGFP-Cl portion of the expression vector. It was confirmed by
restriction enzyme analysis that there were no significant alterations within the expression
vector that would be injected into the embryos. Therefore, to liberate the brazzein
expression vector from the plasmid, the DNA was digested first with Aatii as described
above. Following purification with phenol/chloroform and ethanol precipitation, the DNA
was digested with BamHI using NEBuffer for BamHI and IX BSA at 37°C for 2 hours.
The remainder of the Elutip purification procedure in preparing the brazzein expression
vector was the same as that described above for thaumatin.
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Murine embryo transfer
The following procedure was performed by a team of people in Drs. John Morrey's
and Kenneth White's laboratories (U tah State University, Logan, UT). Mice were kept on
an automatic 5 am - 5 pm light cycle. With embryo collection taking place on day 4, the
treatment regimen for superovulati ng the donor mice was as follows:
Day I : 6U PMSG (Ca!BioChem, San Diego, CA ) (0.85% saline at I U/0. 1 ml) was
injected intra-peritoneally (IP) between I0 :00 am and II :00 am.
Day 3: 6U hCG (Sigma Chemical Co. , St. Louis, MO) (0.85% sali ne at a
concentration of I U/0.1 ml) was given IP between 9 am and I0 am.
Day 4: embryo collection at 8:00am: donors were euthanized by C0 2 inhalation.
Embryos were collected from the ampulla and washed in M2 media that contained
350 JJ.g/ml hyaluronidase (Sigma Chemical Co. , St. Louis, MO). The embryos were
washed with the M2 media, and then hyaluronidase med ia for 15 sec or until the cumulus
cells fell off. They were then washed in M2 media to remove the hyaluronidase. These
embryos were held in wash buffer at 37°C until microinjection was performed.
Microinjection of the brazzein or thaumatin expression vectors into the embryos was done
between 9:30am to 1:00pm on the day of embryo collection. After microinjection the
embryos were transferred into the infundibulum of recipient mice The recipients were
pseudoimpreganted by putting them with vasectomized males at 1 to 5 pm on day 3, so that
the reproductive tract was hormonally prepared to receive the embryos (27).

Screening for potential transgenic
animals
Preparation of samples
The pups from the mice that were implanted with the microinjected embryos were
weaned at about 3 weeks of age, at which time a tail biopsy was taken. Using a razor blade
that had been sterilized by being dipped in 100% ethanol and flamed , 0.5 em was removed
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from the end of the tail and placed in a labeled sterile microcentrifuge tube. The DNA was
isolated by digestion with I00 !lglml proteinase K in I X proteinase K buffer for 12 hours

The samples were not purified by PC/EtOH because this would increase the
likelihood of the samples becoming contaminated.
Screening by PCR
The genomic DNA from putative transgenic mice were screened by PCR using the
primers B+ and C- that were used to generate the individual synthetic thaumatin fragments.
The PCR reaction conditions were as follows: 0.4 11M each primer, IX PFU buffer which
contains 2 mM MgCI 2 (S tratagene, LaJolla, CA), 25 11M dNTP's, I mM MgCI 2 (Gibco
BRL, Grand Island, NY) , 50 !lglml BSA, 1.25 U PFU enzyme and I Ill of DNA template
in a total reaction volume of 25 111. The PCR reaction was performed on all of the animal
samples in addition to various positive and negative controls. When the PCR products
were fractionated on a 2.5 % Seakem LE agarose gel, a faint band was evident in the region
of the predicted size of 345 bp.
Screening by genomic Southern blot
hybridization

In addition to screening by PCR, some of the DNA samples were also screened
using Southern blot analysis of the genomic DNA. The protocol outlined here, was for
genomic DNA but the transfer of the DNA and the probe preparations were the same for the
blots that were done on the agarose gels that contained the fractionated PCR products.
The tail samples that had been digested with proteinase K were purified by
extraction with phenol:chloroform:isoamyl alcohol (Sigma Chemical Co., St. Louis, MO) ,
two chloroform: isoamyl alcohol (24: I) extractions and ethanol precipitation. The
concentration and purity of the samples was determined on a spectrophotometer (Shimadzu
Scientific Instruments, Inc., Columbia, MD) at wavelengths 260 nm and 280 nm after
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suspending the DNA in TE buffer. An amount of tO ~g of eac h DNA sample was digested
with the restriction enzyme Hinfl, which is a four base pair-cutting enzyme, and is not
found in either of the brazzein or thaumatin gene sequences. The digest was done using
NEBuffer #2 at an incubation temperature of 37°C. The digested DNA was then run on a
2% Seakem LE agarose gel. The DNA was transferred to a positively charged nylon
membrane (GibcoBRL, Grand Island , NY) according to the Stratagene PosiblotTM pressure
blotter protocol (Stratagene, La Joll a, CA). After drying overnight the DNA was
permanently bound to the membrane by UV -crossli nking in a Strata-link oven (Stratagene,
La Jolla, CA). To prepare the membrane for addition of the probe, the membrane was
floated , DNA-side up, on top of 6X SSC until the underside of the membrane was
completely wet and the membrane was submerged in 6X SSC for 5 min. The membrane
was placed in a bag with l rnl prehybridization solution (PH) per cm2 of membrane and the
bag was sealed and incubated at 68°C for 15 min.
The DNA template for generating the probe was obtained from the thaurnatin DNA
sequence used to inject embryos. The region to which it bound was indicated in fi gure 14.
It was cut out of pUC plasmid by a double restriction enzyme digestion with the enzymes
BarnHl and EcoRI, NEBuffer for EcoRI, and IX BSA at 37°C for at least l hour. The
probe was prepared by random primer labeling as described in objective# I.
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FIG. 14. Location of probe used in detection oftransgene. The probe was prepared from
the clone that contained the thaumatin gene and signal peptide sequence which was
incorporated into the expression vector. The probe was approximately 700 bp in length .
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The efficiency of the reaction was determined by measuring the percentage of 32 P
nucleotides that were incorporated. The volume of the reaction was brought up to I00 Ill
with TE buffer after I Ill of EDT A was added to stop the reaction. To measure the "before"
radioactive level, I Ill of the reac tion was dotted onto a DES I filter. The remaining 99 Ill of
the reaction was run through a Sephadex G50 spin column at 4,000 rpm for 4 min (30) to
remove any un -incorporated nucleotides. The el utant was removed and I Ill dotted onto
another DES I filter to measure the "after" radioactive level. Using the ratio of the "before"
and "after" radioactive counts, the efficiency of the reaction was determined in terms of
percent incorporation. The percent incorporation was then used to calculate the speci fie
activity. If the probe had a specific activity of 108 cmpl!lg, 5 ng of DNA was used per mJ
prehybridization solution. If the probe had a specific activity of 109 cmp/!lg, 2 ng of DNA
was used per mJ of solution.
To probe the membrane, the PH was drained out of the bag containing the
membranes and fresh PH was added along with the probe. This was incubated at 68°C for
at least 8 hours. The filters were then washed according to high stringency conditions (3)
to remove any unbound probe.
Objective 3: Detection of protein in the milk of tbe transgenic mice

Generation of antibodies to thaumatin
and brazzein
The goat and rabbit antibodies that were used in the assay were generated using the
natural thaumatin protein (Sigma Chemical Co., St. Louis, MO) and a multiple antigenic
peptide of brazzein was synthesized by USU Biotechnology Laboratory.
A 2 mJ volume of 0.25 mg/ml tbaumatin was added to one vial of Ribi Adjuvant
(RIB! lmmunochemicals, Hamilton, MO) tbat had previously been warmed to 37°C. The
mixture was vortexed for a total of four minutes and tben kept at 37°C until the injections
were given. Two goats were injected intramuscularly (IM) with 1.0 ml. Two rabbits were
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injected LM , intradermally and subcutaneously with varying amounts that made a total
volume of0.7 mJ. A third rabbit was injected in the same sites but had a total volume of I
mJ. A booster injection was given I 6 days later.
A volume of 2 mJ of 0.25 mg/mJ brazzein multiple antigenic peptide was added to
one vial of Ribi adjuvant at 37°C. It was injected into rabbits and goats in the same manner
as described above for thaumatin.
The blood was collected from the immunized goats and rabbits 26 days after the
first injection was given. The serum was isolated by centrifugation at 1,200 rpm for 15
min . The serum was transferred to a fresh tube and stored at -80°C to preserve the
antibodies over a long time period. Aliquots of 100 111 were prepared and stored at -20°C
for use in the ELISA.

ELISA
The ELISA was developed to be able to detect varying levels of either thaumatin or
brazzein protein by comparing absorbance levels (0. 0 ., 450nm) of samples that contained
unknown concentrations of the protein to the 0.0. of known concentrations of protein.
Positive and negative controls were incorporated into the assay. Negative controls
contained all reagents except for the antigen. Positive controls contained varying known
concentrations of antigen.

Substrate
Anti-Rabbit lgG Enzyme conjugate

Antigen (B razzein!Thaumati n)
Goat Capture Antibody

FIG. 15. Des ign of ELISA. The goat capture antibody was bound to the microliter
plate. After blocking of the plates, thaumatin or brazzein antigen was added.
Subsequently the rabbit antibody was incubated followed by the anti-rabbit IgG horseraddish peroxidase conjugate and its substrate.
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The components of the ELISA were added in the order shown in figure 15. A
checker-board design was used for the assay to detennine the appropriate levels of antibody
to be used. Goat antibody was used at log 10 dilutions between 1 X

w·' and 1 X 10·'.

Antigen was added at log 10 dilutions from I00 !J.g/ml down to 0.0 I !J.g/ml. The dilution s
were done both in milk and in phosphate buffered saline (PBS) to see what effect the milk
had on the sensitivity of the assay . Rabbit antibody was used at log 10 dilutions from 1 X
Io·2 to I X Io·'. The next two steps in the ELISA were added at a constant level in
accordance with the manufacturer' s instructions.
Dilutions of the goat capture antibody were made in a bicarbonate coating buffer
(7 .35g NaHC0 3 , 1.36g

N~C0 3 ,

900 ml dH 2 0 adjust pH to 9.4, dH 2 0 to 1 L). A volume

of 50 !J.I of the different concentrations of goat antibody were pipetted into the assigned
wells of Irnrnulon™ ELISA plates (Intermountain Scientific Corporation, Kaysville, UT).
The plates were gently tapped to ensure that the bottom of the well was covered. This was
done after each step in the ELISA. The plates were covered and stored at 4°C for a
minimum of 12 hours. The wells were emptied by flicking the plates over a sink. The
plates were washed by pipeting 200 !J.l of wash solution (IX PBS) into each well and the
wash solution removed by flicking the plates. This was repeated twice. The next step
involved blocking the wells so that the antigens added in later steps would not bind to the
sides of the wells. A volume of 100 !J.l of ELISA blocking solution (0.025M PBS, 0.05 %
Tween 20, 0.5% Gelatin) was put into each well. The plates were covered and incubated
for 1 hour at 37°C. The plates were then washed as described above . The antigen was
added at the specific concentration in a volume of 50 !J.l per well. Dilutions of antigen were
made in the IX PBS wash buffer or in bovine milk. The plate was covered and incubated
for 1 hour at 37°C. The plates were then washed. A volume of 50 !J.l of serially diluted
rabbit antibody in wash buffer was added to each well. After incubation for 1 hour at
37°C, the rabbit antibody was removed by washing the plates. An anti-rabbit antibody
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conjugated to horse radish peroxidase (Si gma Chemical Co. , St. Loui s, MO) was prepared
accordin g to the manufacturer's instructions, stored at 4 °C, and kept away from UV light.
A I : I 00 dilution of the conjugate was made in wash buffer just prior to its addition to the
plate. A volume of 50 111 of conjugate was pi petted into each well and the plate was
covered and incubated for I hour at 37°C. Once again the plates were washed. The
substrate for the horse radish peroxidase was ortho-phenylenediamine dihydrochloride
(OPD) (Sigma Chemical Co., St. Louis, MO). The OPD solution was prepared according
to the package insert that came with the OPD tablets. A volume of 50 111 of the OPD
solution was pi petted into each well , and the plates were covered and incubated at room
temperature in the dark. The plate was read after 10-15 min on an ELISA plate reader at
450 nm.

Collection of mouse milk
Mouse milk was collected during the lactation period using a method described in
Maga et a!. (22). The lactating mice were injected with oxytocin (Sigma Chemical Co. , St.
Louis, MO) and milked by a specifically designed suction device (gift from the original
author; James Murray, University of California, Davis). The volume of milk obtained
varied from 20 111 to 200 111. The milk was collected into a microcentrifuge tube and stored
at -20°C until used.

Analysis of mouse milk proteins by
capillary electrophoresis (CE)
Some of the putative thaumatin transgenic mouse milk samples were analyzed by
CE by Marie Strickland, Department of Nutrition and Food Sciences, Utah State
University. A positive control was prepared for the CE by adding the native plant
thaumatin obtained from Sigma to the milk of non-transgenic mouse milk. The negative
control consisted of milk from non-transgenic mice or transgenic mice carrying an unrelated
trans gene. A range of 20 to 50 111 of milk was mixed with 3 volumes of 9 M urea, I 00 mM
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phosphoric acid solution and stirred for 30 min. The resulting pH was well below the
isoelectric point of all common bovine milk protein s. The 9 M urea disrupted the micelles
and dissolved the proteins in milk. The extracts were centrifuged at top speed in an
Eppendorf centrifuge. The clear solution below the floating lipid layer was removed,
filtered through a 0.2-!lm low protein binding syringe filter, and diluted 5- to 10-fold
before CE. The run buffer was 4 M urea, 100 mM phosphate pH 3.35. This pH was
below the isoelectric point of most milk proteins so that they are positively charged in
solution. The pi of thaumatin was calculated to be greater than II using the GCG
computer analysis program. Migration towards the negative electrode depended on the
charge density of the molecules. The small, highly positive charged species eluted first ,
followed by larger, less charged species. Ultraviolet light at 210 nm was used for detection
of the bands.
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MATERIALS

Seapl aque GTG agarose
- from FMC Bioproducts, Rockland, ME
-cat.# 50 11 3
Nuseive GTG agarose
- from FMC Bioproducts, Rockland, ME
-cat.# 50082
Sea kem LE agarose
- from FMC Bioproducts, Rockland, ME
- cat# 50004
E thidium bromide
-from Sigma Chemical Co., St Louis, MO
- cat. # E-8751
Proteinase K
- from Sigma Chemical Co. , StLouis, MO.
-cat. # P-2308
Sodium dodecyl sulfate (S DS)
- from Acros Organics, NJ.
-cat. #41953-0010
E DTA
- from Sigma Chemical Co., St Louis, MO.
-cat. #E-5134
Tris
- from Acros Organics, NJ .
-cat.# 42457-5000
Phenol chloroform
- from Sigma Chemical Co., St Louis, MO.
-cat. #P-3803
pGFP-Cl
- Clontech, Palo Alto, CA
- cat. #6094- 1
Bacto® tryptone
- Difco laboratories (ordered through Fisher Chemical Co.)
-cat. #0123-17-3
Bacto® yeast extract
- Difco laboratories (ordered through Fisher Chemical Co.)
-cat. #0886-17-0
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Sodium Chloride
- from Mallinckrodt, Paris, KY
-cat. #7581
Bacto-agar
-from Becton Dickinson and Company, Cockeysville, MD.
- cat. # 4311849
Kanamycin
- from Sigma Chemical Co., StLouis, MO
- cat.# K-4000
ATP
- from Sigma Chemical Co., St Louis, MO.
-cat.# A-2383

dNTP 's
-from Pharmacia, Piscataway, NJ .
-cat. #27-2035-01
B SA
- from Pentex, Kankakee, IL.
-cat. #81-001-2

Ampicillin
- from Sigma Chemical Co. , StLoui s, MO.
-cat# A9518
IPTG
- fro m Sigma Chemical Co., StLouis, MO.
-cat # I 5502

X-ga l
- from Sigma Chemical Co., StLouis, MO.
-cat# B 4252

1 kb ladder
- Gibco BRL, Grand Island, NY.
-cat.# 56 15 SA
Lambda Hind III
-from New England BioLabs, Beverly, MA
-cat.# 30l-2S
XL l-Blue Epicurian Coli Electroporation-Competant Cells
- from Stratagene , La Jolla, CA.
- cat. # 200236
Nitrocellulose membrane
- from Schlieher & Schuell, Keene, NH
-cat. #20470
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P dCTP
- ICN Biochemicals, Costa Mesa, CA
-cat. #3901 IX

Sodium citrate
- from Sigma Chemical Co., StLouis, MO
- cat. #C-9795
Thaumatin
- from Sigma Chemical Co., StLouis, MO
-cat.# T-7638
Nylon Membrane
- from Gibco BRL, Grand Island, NY
-cat.# 14856-017
Res triction enzymes:
Aat II
- from New England BioLabs, Beverly, MA
-cat.# 117S
Age I
-from New England BioLabs, Beverly, MA
-cat.# 552L

Bam HI
-from New England BioLabs, Beverly, MA
-cat. # 136L
Dde I
-from New England BioLabs, Beverly, MA
-cat. #l75S

Eco RI
- from New England BioLabs, Beverly, MA
-cat. #!OIL
Hind III
-from New England BioLabs, Beverly, MA
-cat. #l04S
Kpn I
-from New England BioLabs, Beverly, MA
-cat. #142L

Ppum I
-from New England BioLabs, Beverly, MA
-cat. #506S
Sal I
-from New England BioLabs, Beverly, MA
-cat. #I38S
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Sma I
- fro m New England BioLabs, Beverly, MA
-cat.# 14 1S

Spe I
-from New England BioLabs, Beverly, MA
-cat.#I33S

E nz ymes:
Taq polymerase
- Gibco BRL, Grand Island, NY .
- 8038SA
T4 DNA polymerase
-from New England BioLabs, Beverly, MA
-cat. #203S
Polynucl eotide kinase
- from New England BioLabs, Beverly, MA
-cat. #2 10S
T4 DNA ligase
- from New England BioLabs, Beverly, MA
- cat. #202S
Beta-aga rase
- from New England BioLabs, Beverly, MA
-cat. #392L
Sequ enase
- from USB , Cleveland, OH
-cat. #70722
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RESULTS
Objective I: Construction of expression vector
This results section gives the data obtained from the experiments described in the
experimental methods section. The results are given under the same headings and
subheadings that were used in the methods section so as to facilitate comparison between
the two sections.
Reaction (rxn) and gel numbers, used in the laboratory to trace experimental data,
have been noted for some of the important reactions to provide continuity between the
thesis and the raw data.
In all of the argarose or polyacrylamide gel electrophoresis shown, one of two
standard size markers was used: A. Hind III size marker (New England Biolabs, Beverly,
MA) or I kb ladder (Gibco BRL, Grand Island, NY). The sizes for the bands seen with
these are shown below (figure 16) and should be referenced to as needed.

JLambda Hind III
_ _.23,130 bp
- -9,416
- -6,557
- -4,361
_ _ 2,322
- -2,027

I kb ladder
- - 4,072 bp
- -517
--506
--396
- -344
~98

--564

123

___)20
- -20 1
_ _ 154
- - 1 34
75

FIG. 16. Marker size map.
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Cloning 11-casein regions into pGFP-C l
Isolating 13-casein fragments
The 4.4 kb 5' 13-casein region obtained by PCR was fractionated on a I% LE
agarose gel. The diagnostic 4.4 kb band was demarcated by an arrow on the gel (figure
17). The 2.2 kb 3' 13-casein region obtained by PCR was fractionated on a I% LE agarose
gel (fi gure 18). The diagnostic 4.4 kb band was demarcated by an arrow on the gel. Only
a smal I proportion of each PCR reaction was fractionated by gel electrophoresis for
analytical purposes; the remainder of the 5'13-casein PCR product was ligated into pGFPC I as described below.
Cloning of 5'13-casein DNA into pGFP-CI
DNA isolated from the colonies resulting from the ligation of 5'13-casein with
pGFP-C I was fractionated on a I% LE agarose gel without restriction enzyme digestion.

FIG. 17. 5' 13-casein DNA region obtained by PCR.
Lane I: A. Hind ill size marker (New England Biolabs, Beverly, MA) ;
Lane 2: PCR reagent negative control (no DNA template added) ;
Lanes 3-8: 5' 13-casein PCR product.
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FIG. 18. 3' B-casein DNA region obtained by PCR.
Lane 1: AHind III size marker;
Lanes 6-8: 3' B-casein PCR product.
As a comparison, the uncut pGFP-Cl plasmid was also loaded onto the gel so that the
control band could be visualized (figure 19). Those clones that had different size bands
than the plasmid band were considered possible candidates for the correct clone because the
different migration patterns indicated that the size of the plasmids had changed due to
ligation of inserts. Because the plasmids were not linearized it was not possible to predict
the size of bands seen on the gel. However, the plasmids that had a different
electrophoresis pattern than the control were screened by restriction enzyme digestion.
In figure 19 below, and the following figures that show the cloning of 5' and 3' Bcasein DNA, the only clone that was ultimately used in the expression vector is indicated by
an arrow. Those clones in figure 19 that had an uncut lower band of approximately 6 kb
were possible candidates that contained the 5'B-casein.
Examples of such bands in figure 19 are in lanes 4 and 14. These were cut with the
restriction enzymes Aatii and Agel in a double digestion reaction which, in a correct clone,
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FIG. 19. Screening of 5'13-casein into pGFP-Cl (gel #763).
Lanes I 15 and 16: A. Hind III size marker;
Lanes 2 and 17 : uncut pGFP-Cl ;
Lanes 3- 14 and 18-24: uncut putative p5'13cas clones (Rxn # 3531 ).
would liberate the 5'13-casein from the pGFP resulting in two bands of similar size, a 4.4
kb and 4.7 kb band. A second diagnostic digestion with Spel was done which would cut
the plasmid in two sites generating a 7.3 and 1.8 kb band. These diagnostic enzyme
digestions were fractionated on a I% LE agarose gel (figure 20).
The digest with Aatii and Agel of the clone, seen in lane 3 of figure 20, appeared
to contain one thick band at approximately 4.5 kb. This was interpreted to be a result of
loading too high of a DNA concentration onto the gel so that it was not possible to
differentiate two bands. The digest with Spel liberated the two predicted bands and a third
band which was probably DNA that was not digested (lane 6). The clone shown by the
arrows in figures 19 and 20 was then sequenced by the USU Biotechnology Laboratory.
It was sequenced across the signal peptide sequence as well as from the 3' end of the 5' B-
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casein region. The sequencing results were compared to the published sequence of the
bovine B-casei n gene using the Wisconsin GCG Sequence Analysis Software Package .
The sequence which originated from the 3' end of the S' B-casein region is shown in figure
21. Part of the restriction enzyme si te ACCGGT that is recognized by Agel was
highlighted to orientate the data in relation to how it fits into the expression vector (figure
7). The errors seen at either end of the sequences that are shown throughout this chapter
maybe as a result of sequencing artifacts and therefore could not be considered true errors
in the sequence. Errors at the beginning of sequencing and at the terminal end when
seq uencing beyond 300-400 bases are common artifacts of sequencing.
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FIG. 20. Screening of putative pS ' Bcas clones (gel# 765).
Lane I: A. Hind III;
Lanes 2 & 3: putative clones, from lane 4 & 14 in figure 18, cut with Aatii
and Agel;
Lanes 5 & 6: putative clones, from lane 4 & 14 in figure 18, cut with Spei.
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494 AGGACCAAAAGTGAGTNATATGGCATAAATACAATNGCATGCATATACAA 445
II II 1111111111 : II II 111111 1 111111= 11111111111111
4047 AGAACAAAAAGTGAGTAATATTGCATAAATACAATTGCATGCATATACAA 4096
444 TCTAGATAAATATATCTTATTCCAGTGATGAAATATTTGTATCCCTTACT 395
11111111111111111111111111111111111111111111111111
4097 TCTAGATAAATATATCTTATTCCAGTGATGAAATATTTGTATCCCTTACT 4146
394 GTAGAGTGCTAGGTTTAGCTGTGTCTATTCAACACAGGATGATACTCCAG 345
1 111111111111111111 11 11111111111111111111111111111
4147 GTAGAGTGCTAGGTTTAGCTGTGTCTATTCAACACAGGATGATACTCCAG 4196
344 AGGATGGTATATCAGACAACAATAATAAATATGTTCATAATTATAATAAA 295
11111111111111111111111111111111111111111111111111
4197 AGGATGGTATATCAGACAACAATAATAAATATGTTCATAATTATAATAAA 4246

294 AAGTGTTCAGTAAAAATTAAAATAACTCCTTTTCTGTTACCCATAAAAAC 245
1 1 1 1111111111111111 1 111111111111 1 1 1 111 111111111 1 1 1
4 247 AAGTGTTCAGTAAAAATTAAAATAACTCCTTTTCTGTTACCCATAAAAAC 4296
244 TCTTCATTAAAGTAAAACAAAAATATACTAATGAAAGTTACTAAATTTAA 195
11111111111111111111111111111111111111111111111111
4297 TCTTCATTAAAGTAAAACAAAAATATACTAATGAAAGTTACTAAATTTAA 4346
194 AAGACTCTCAAAAGACATATAACATTTTTATTTTTCAGATTTGTGAAATA 145
1111111 111 1 11111 1 111111111111111111111111111111111
4347 AAGACTCTCAAAAGACATATAACATTTTTATTTTTCAGATTTGTGAAATA 4396
144 GATAGCTCTGAATAAAGCAAGTAAAAATTAGGTAGGAAAATATTTAATAA 95
1111111111111111111111 1 111111111111111111 111111111
4397 GATAGCTCTGAATAAAGCAAGTAAAAATTAGGTAGGAAAATATTTAATAA 4446
94 TGAGTTGACTGTGGGAACTAAAGTGTTTTTTTTTCTCTTTAGCTGGAAGA 45
1111 11 111111111111111111111111 1 1111111 1 11111 11 1111
4447 TGAGTTGACTGTGGGAACTAAAGTGTTTTTTTTTCTCTTTAGCTGGAAGA 4496
Age I

44

ACTCAATGT~

31

111111111111 I
4497 ACTCAATGTACCTG 4510

FIG. 21. Sequence comparison between the cloned and published sequences of 5'
portion of B-casein. The top line starting at position 494 is the sequence obtained from our
DNA sequence cloned into pGFP-C l and the bottom line is the sequence of the bovine Bcasein gene (accession #xl4711 ).

61
Cloning 3'13-casein DNA into pUC-19
A schematic of the cloning of3'13-casein into pUC- 19 is shown in figure 22. It
illustrates the possible orientation in which the 3' 13-casein insert could have ligated into the
pUC plasmid. Putative clones with the DNA insert of 3'13-casein region cloned into pUC19 in either orientation were identified as shown on the following I % LE agarose gels
(figures 23-24). Figure 23 contai ned the undigested putative 3'13-casein-pUC clones. As
explained in section 2 for figure 19, the uncut clones that had bands with a different
migration pattern when compared to the uncut pUC 19 were considered candidates for
containing the 3'13-casein insert. These putative clones were then definitively diagnosed
using restriction enzyme digestion.
Those samples in figure 23 that had a lower band of approximately 3 or 4 kb, as
connoted by an arrow, (for example lanes 14 and 16) were subjected to restriction enzyme
analysis to confirm that they contained the 3' 13-casein. The size of the bands varied

ORIENTATION #1

3' Beta-casein 2220 bp

ORIENTATION #2

3' Beta-casein 2220 bp
Bam HI

Hind Ill

FIG. 22. Two possible orientations of cloning 3' 13-casein DNA
sequences into pUC-19.

Kpn I
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FIG. 23. Screening of putative 3' 13-casein-pUC 19 (gel #752).
Lanes I. 20, 21 & 33: A Hind III marker;
Lanes 2-18 & 22-31: uncut putative 3' 13-casein-pUC clones (Rxn# 3505);
Lanes 19 & 32: uncut pUC.
according to the orientation in which the 3' 13-casein had ligated into the pUC-Smai enzyme
site (figure 22). In the first enzyme digestion done with Kpnl, two bands of 2.7 and 2.2
kb for orientation I (figure 24) or 4.8 kb for the second orientation were seen (figure 24).
The second enzyme digestion was a Hindiii digestion that would liberate similar size
bands for both orientations.
Several of the clones, shown by arrows in figure 24, that were likely candidates
for the correct insert were sequenced by the USU Biotechnology Laboratory. The cloned
sequences were aligned with the published sequences by the Bestfit program in the GCG
Sequence analysis package. The sequence of the clone used in the expression vector was
matched to the native sequence of the 13-casein gene as shown in figure 25. The errors
seen at either end of the sequence are probably sequencing artifacts and cannot be
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FIG. 24. Screening putative 3'13-casein-pUC clones (gel #754).
Lanes 1.8.19 & 30: A. Hind ill size marker;
Lanes 9-18: putative 3'13-casein-pUC clones cut with Kpn I;
Lanes 20-29: putative 3'13-casein-pUC clones cut with Hind ill.
considered true errors in the sequence. Errors at the beginning of sequencing and at the
terminal end when sequencing beyond 300-400 bases are common artifacts of sequencing.
Subcloning 3'13-casein DNA into p5'B-cas
construct
After ligating the 3'13-casein DNA into p5 '13-cas, the initial screening was done by
colony hybridization using a radiolabeled probe specific for the 2.2 kb 3'13-casein DNA
segment. Colonies of interest that showed up as dense areas on the autoradiograph were
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41 CCAGGATGGGTACCAGGATAAAATCCACCCCTTTGCCCAGACGCAGTCTC 90
11111111

111111111111111111111111111111

1111111

8024 CCAGGATGAACTCCAGGATAAAATCCACCCCTTTGCCCAGACACAGTCTC 8073
91 TAGTCTATCCCTTCCCTGGGCCCATCCATAACAGCCTCCCACAAAACATC 140
1111111111111111111

111111111111111111111111111111

8074 TAGTCTATCCCTTCCCTGGACCCATCCATAACAGCCTCCCACAAAACATC 8123
141 CCTCCTCTTACTCAAACCCCTGTGGTGGTGCCGCCTTTCCTTCAGCCTGA 190
1111111111111111111111 1 11111 1 111 1 11111111111111111

8124 CCTCCTCTTACTCAAACCCCTGTGGTGGTGCCGCCTTTCCTTCAGCCTGA 8173
191 AGTAATGGGAGTCTCCAAAGTGAAGGAGGCTATGGCTCCTAAGCACAAAG 240
11111111111111111111111111111111111111111111111111

8174 AGTAATGGGAGTCTCCAAAGTGAAGGAGGCTATGGCTCCTAAGCACAAAG 8223
241 AAATGCCCTTCCCTAAATATCCAGTTGAGCCCTTTACTGAAAGCCAGAGC 290
11111111111111111111111111111111111 11 1 1 11111111111

8224 AAATGCCCTTCCCTAAATATCCAGTTGAGCCCTTTACTGAAAGCCAGAGC 8273
291 CTGACTCTCACTGATGTTGAAAATCTGCACCTTCCTCTGCCTCTGCTCCA 340
11111111111111111111111111111111111111111111111111

8274 CTGACTCTCACTGATGTTGAAAATCTGCACCTTCCTCTGCCTCTGCTCCA 8323
341 GTCTTGGATGCACCAGCCTCACCAGCCTCTTCCTCCAACTGTCATGTTTC 390
11111111111111111111111111111111111 1111 11111111111

8324 GTCTTGGATGCACCAGCCTCACCAGCCTCTTCCTCCAACTGTCATGTTTC 8373
391 CTCCTCAGTCCGTGCAGTCCCTTTCTCAATCCAAAGTCCTGCCTGTTCCC 440
1111111 11111111

111111111111

111111111111111111111

8374 CTCCTCAGTCCGTGCTGTCCCTTTCTCAGTCCAAAGTCCTGCCTGTTCCC 8423
441 CAAAAAGCAATGGCCTATCCCCAGAAAAATATG.CCATTCAGGGCTTTCT 489
II

111111

II

111111111 1 11

I

IIIII

1 11111111

111111

8424 CAGAAAGCAGTGCCCTATCCCCAGAGAGATATGCCCATTCAGGCCTTTCT 8473
490 GCTGTA.CAAGAACCTGTA.TCNGTCCTGTCCGGGAAC 525
111111

II

II

111111

II: 111111111111

II

8474 GCTGTACCAGGAGCCTGTACTCGGTCCTGTCCGGGGAC 8511

FIG. 25 . Sequence analysis of 3' portion of B-casein cloned into pUC. The top line is
the sequence obtained from DNA cloned into pUC 19. The bottom line is the sequence of
the bovine B-casein gene (accession #Xl4711).
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Subclonin g 3'B-casein DNA into p5 'B-cas
construct
After ligati ng the 3' 13-casein DNA into p5 'B-cas, the initial screening was done by
colony hybridization using a radiolabeled probe specific for the 2.2 kb 3' B-casein DNA
seg ment. Co lonies of interest that showed up as dense areas on the autoradiograph were
matched to the original agar plate that contained the bacterial colonies. The plasmid DNA
was isolated and further screened by restriction enzyme analysis to identi fy p5 '3'13-cas
clones.
The samples were screened by several different diagnostic enzyme digestion
reactions. The reactions were Hindiii, a double digest using BamHI and Kpnl, and Sail
and Xbal.

FIG. 26. Autoradiograph of colony hybridization to detect p5 '3' 13cas.

66
Figure 27 shows the Hindill digested-plasmid DNAs of all the colonies that were
isolated from the plates. For each clone, the uncut samples were run next to the
correspond ing samples that were cut with Hind III (see legend for figure 27 for
identification of the samples). This aided in accounting for different size bands that were
visible on the agarose gel due to incomplete restriction enzyme digestion.
The DNA samples tentatively identified in figure 27 were cut by several enzymes
as indicated above (figure 28). All of the predicted sized bands correlated with the actual
sizes, except for the plasrnids cut with Xbai. Lanes 2-5 all exhibit the predicted bands for
a correct clone that was digested with BamHI and Kpnl. In lanes 7- 10, the upper band

FIG. 27. Screening ofp3'5'B-cas #I (gel# 945).
Lanes I & 21: A. Hind ill size marker;
Lanes 6,16,26 & 36: pGFP5 'B-casein cut with Kpnl;
Lanes 2-5,7-10 12- 15 17-20 22-25 27 30 & 12-15: alternating uncut
sample next to sample cut with Hindill.
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FIG. 28. Screening of putative p3'5'B-cas #2 (gel #946) .
Lanes I ,6 & II: A. Hind III size marker;
Lanes 2-5: putative 3'5'B-casein clones cut with BamHI and Kpnl;
Lanes 7-10: putative 3'5'B-casein clones cut with Sail;
Lanes 12-15: putative 3'5'B-casein clones cut with Xba I.
has shifted upwards slightly when compared to the upper band in lanes 2-5. This upper
band at approximately II kb was diagnostic of a correct clone. It was determined on the
basis of this and other restriction enzyme digestions as well as from sequencing data (not
shown) that our 5'3-casein region did not have all the Xbal restriction enzyme sites that
were expected based on the published sequence. Lanes 3 and 8 contain the same plasmid
that was used for the expression vector.

Generating separate segments of the
synthetic genes
Amplification using PCR
As outlined in figures 8 and 9, the thaumatin and brazzein genes respectively were
amplified by PCR. In the initial attempt to amplify thaumatin and brazzein DNA using
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PCR, the reaction s used the buffer supplied with the polymerase. The MgCI2
concentrations were varied. This resulted in multiple bands as could be seen on the
ethidium bromide stained 2.5 % Seaplague GTG agarose gel in figure 29.
Optimization buffers were used to optimize the PCR reaction so that some of the
extraneous bands would be eliminated. The buffers differed in pH and MgCI 2
concentration. The PCR cycling conditions and other reaction conditions s uch as primer
concentrations were not altered from the previous reaction that was run in figure 29. The
results from this PCR are shown in figure 30.
Figure 30 shows the results for brazzein and three of the thaumatin fragments.
The remaining thaumatin D fragment was analyzed on separate gel (figure 31 ). The PCR

FIG. 29. Synthetic gene amplification (gel# 843).
Lanes I 18 & 19: I kb ladder size marker (Gibco BRL, Grand Island, NY);
Lanes 3-5 & 8-11: brazzein PCR with I mM, 2 mM or 3 mM MgCI2 added;
Lanes 13-15: thaumatin A PCR with I mM, 2 mM or 3 mM MgCI 2 added;
Lanes 21-23: thaumatin C PCR with I mM, 2 mM or 3 mM MgCI 2 added;
Lanes 26-28: thaumatin B PCR with I mM, 2 mM or 3 mM MgCI 2 added;
Lanes 6.11.16.24 & 29: negative control for each reaction.
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product, using thaumatin D as the template, was fractionated on a 2.5% Seaplague agarose
gel (figure 31 ).
In fi gures 30 and 31 , the predominant PCR bands of the brazzein, thaumatin A, B,
and D reactions, were the bands of the predicted size. In some of the lanes, additional
bands could be seen, but they were of low abundance. This was adequate to use for
cloning the PCR products into pUC. The PCR product from this reaction for thaumatin
C, however, could not be used due

to

the almost nonexistent band. The thaumatin C PCR

product seen in figure 29, lane 23 was used for cloning the DNA into pUC because of its
abundance.

FIG. 30. Synthetic gene amplification using optimization buffers# 1 (gel #846).
Lanes 1. 11. 21 & 31: 1 kb size marker;
Lanes 2-10: brazzein PCR using optimization buffers A, C, G, H, I, K, L & P;
Lanes 12-20: thaumatin A PCR using optimization buffers A, C, G, H, I, K, L & P;
Lanes 22-30: thaumatin B PCR using optimization buffers A, C, G, H, I, K, L & P;
Lanes 32-40: thaumatin C PCR using optimization buffers A, C, G, H, I, K, L & P.
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FIG. 31. Synthetic gene amplification using optimization buffers #2
(gel #847).
Lane I: I kb size marker;
Lane 2-10: thaumatin D PCR using optimization buffers A , C, G, H , I, K ,
L&P.
Ligation and screening of ligation products
White colonies carrying clones with DNA inserts identified on the basis of lac Z
(blue-white) selection were picked from the plates, and the DNA was isolated and
subsequently diagnosed by digestion with BamHI and EcoRI. Each of these enzyme sites
(BamHI and EcoRI) was located either to side of the Smal site in pUC into which the
fragments were cloned and not in the fragment itself.
The lanes that contained diagnostic lower bands ranging from 160 bp to 230 bp,
depending on which thaumatin fragment was used, were considered putative positive
clones: thaumatin A: lane 4 , thaumatin B: lanes 8 & 10, thaumatin C: lanes 16 & 17,
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FIG. 32. Screening of thaumatin-pUC (gel# 841).
Lanes 1.18.19 & 29: 1 kb size marker;
Lanes 2-5: putative thaumatin A cloned into pUC cut with BamHI and EcoRI;
Lanes 7-12: putative thaumatin B cloned into pUC cut with BamHI and EcoRI;
Lanes 14-16: putative thaumatin C cloned into pUC cut with BamHI and EcoRI;
Lanes 20-27: putative thaumatin D cloned into pUC cut with BarnHI and EcoRI.
thaumatin D: lanes 24 & 25 (figure 32). Figure 33 showed brazzein DNA insert cut out of
the pUC plasmid with Ppuml and Sail, which were the enzymes sites on either side of the
brazzein synthetic gene. The gel was an 8% polyacrylamide gel, which provided more
precision for estimating the relative sizes of the bands. A brazzein diagnostic band at
approximately 200 bp was apparent in lanes 6 through 8 of figure 33.
The modified protocol for cloning these oligonucleotides was important, because a
high number of random errors were seen when using the unmodified protocol. An
example of a sequence containing multiple errors is shown below in figure 34. A high
frequency of random errors were seen in DNAs generated from the original, unmodified
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FIG. 33. Brazzein digested out of pUC (gel# 805).
Lane I: 123 bp ladder (Gi bco BRL, Grand Island, NY) ;
Lanes 5- 10: putative brazzein-pUC clones.
nucleic acid synthesis procedure. The errors are spuriously located throughout the
sequence in figure 34, without any predictable pattern. Therefore, some of the brazzein
and thaumatin fragments had to be remade using a modified procedure with a longer
deprotection time (overnight instead of several hours) and lower temperature (60° C
instead of 80° C). This modified procedure yielded far fewer errors in the oligonucleotide
sequences. The number of errors for each oligonucleotide varied. Therefore, instead of
remaking the oligonucleotides for the thaumatin fragments A and D, a high number of
putative clones were sequenced until a complete error-free sequence was found for both A
and D. The following series of figures (34-38) shows the sequences of the synthetic DNA
with the predicted sequences. The correct error-free sequences showing the correct
brazzein and thaumatin clones were given after the sequence that contained random errors
(figure 33). In each figure the sequence obtained from the synthetic clone is on the upper
row. The synthetic sequence (top row) was compared to the predicted sequence (lower
row) that was used in the design of the expression vector (figures 5 and 6).
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Figure 34 shows a number of errors that occurred in the PCR-cloned thaumatin C
fragment. In other clones from the PCR reaction, different errors were seen. With the
modifications in the deprotection protocol given above, the number of errors was
significantly reduced. A varying number of clones for brazzein and each thaumatin
fragment were sequenced until one was found which had a perfect sequence when
compared to the predicted sequence.
The sequence of the brazzein cloned into pUC was shown on the top line of each
row in figure 35. Each nucleotide of the clone matched with the predicted sequence for this
3 ANATCTGGGNCAGAAC . . ACTGCTATTTTGACGATAGAGAAAGAGGCATC 50
1 ,111 1 11 1, 111111
1111111111111111111 I 111 1 111111
193 agatctgggccagaaccgactgctattttgacgatagcggaagaggcatc 242
51 AGCCGGACCGGCGGACTGTGGCGGACTGTTGCAGTGGAAAAGATTTGGCA 100
11111111111 111111111111111 1111111 II 1 111111111
243 tgccggaccggc.gactgtggcggactgctgcagtgcaagagatttggca 291
101 GACCTCCTACGACTCTGGCTGAATT 125
1111111111 1 111111 111 1 II
292 gacctcctaccactctggctgagtt 316

FIG. 34. Sequence analysis of a thaumatin C clone that contained multiple errors.
This clone is an example of one that was prepared using the unmodified protocol.
3 CTGCCTGGTGGCCGTGGCCCTGGCCGACAAGTGCAAGAAGGTGTATGAGA 52
11111111111111111111111111111111111111111111111111
23 ctgcctggtggccgtggccctggccgacaagtgcaagaaggtgtatgaga 72
53 ACTATCCTGTGAGCAAGTGCCAGCTGGCCAACCAGTGCAACTATGACTGC 102
1111111111111 1 11 1 11 11111 11 1 1 1 1 1 111 1111 1 1 1 11 1 1 1 111 1
73 actatcctgtgagcaagtgccagctggccaaccagtgcaactatgACTGC 122
103 AAGCTGGACAAGCACGCCAGAAGCGGCGAGTGCTTTTATGACGAGAAGAG 152
11111111 1111 1111111111111 1111111111111111111111111
123 AAGCTGGACAAGCACGCCAGAAGCGGCGAGTGCTTTTATGACGAGAAGAG 172
153 AAACCTGCAGTGCATCGGCGACTATTGCGGCTAGTAAGTCGACGCGGCG 201

I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II
173 AAACCTGCAGTGCATCGGCGACTATTGCGGCTAGTAAGTCGACGCGGCG 221

FIG. 35. DNA sequence of synthetic brazzein (rxn: 3786#4, upper row) as
compared to the predicted sequence (lower row).
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for thi s particular clone, which was used to construct the vector.
The sequence of the thaumatin segment that was cloned into pUC is shown on the
top line of each row for each of the thaumatin fragments (figures 36-39). All of the
nucleotides matched with thaumatin A DNA (figure 35), except for 167 position. Since
3 CTGCCTGGTGGCCGTCGCCCTGGCCGCCACCTTTGAGATCGTGAACAGAT 52

II IIi 111111111111111111111111111111111111111111111
23 ctgcctggtggccgtcgccctggccgccacctttgagatcgtgaacagat 72
53 GCAGCTATACCGTGTGGGCTGCCGCTAGCAAAGGCGATGCCGCCCTGGAT 102

I I I II II I I II II I I I I I I I I II II I II II I I II II I I I I I I I I I I I I I I
73 gcagctataccgtgtgggctgccgctagcaaaggcgatgccgccctggat 122
103 GCCGGAGGCAGACAGCTGAACTCCGGCGAGAGCTGGACCATCAACGTGGA 152

I I I I I I I I II I I II I II I I I I II I I I II II I I II I I I II I II I I I I I I II
123 gccggaggcagacagctgaactccggcgagagctggaccatcaacgtgga 172
153 GCCCGGTACCAAGGCCG 169

11111111111111111

173 gcccggtaccaagggcg 189

FIG. 36. DNA sequence of correct thaumatin A (rxn: 3787 # 12, upper row) as
compared to the predicted sequence (lower row) .

41 GAGCCCGGTACCAAGGGCGGCAAGATCTGGGCCAGAACCGACTGCTATTT 90

I I I I II II II II II I I I I II I II I II II I I I I II I II II I I I II II I I I I

171 gagcccggtaccaagggcggcaagatctgggccagaaccgactgctattt 220

91 TGACGATAGCGGAAGAGGCATCTGCCGGACCGGCGACTGTGGCGGACTGC 140

I I I I I I I I I I I I I I I I I I II I I II I II II I I I II I I II I I I I I II I I II I
221 tgacgatagcggaagaggcatctgccggaccggcgactgtggcggactgc 270
141 TGCAGTGCAAGAGATTTGGCAGACCTCCTACCACTCTGGCTGAGTTTAGC 190

11111111111111 11 111 1111111111111111111111111111111
271 tgcagtgcaagagatttggcagacctcctaccactctggctgagtttagc 320
191 CTG 193

Ill
321 ctg 323

FIG 37. DNA sequence of correct thaumatin B (rxn : 4059 #8 upper row) as
compared to the predicted sequence (lower row).
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37 TCCCCCTCTGGCTGAGTTTAGCCTGAACCAGTATGGCAAGGACTATATCG 86
I II 111111111111111111111111111111111111111111111
299 taccactctggctgagtttagcctgaaccagtatggcaaggactatatcg 348

87 ATATCAGCAACATCAAGGGCTTTAATGTGCCTATGGACTTTAGCCCTACT 136
11111111111111111111111111111111111111111111111111

349 atatcagcaacatcaagggctttaatgtgcctatggactttagccctact 398
137 ACCAGAGGCTGCAGAGGCGTGAGATGCGCTGCCGACATCGTCGGCCAGTG 186
11111 1 1111111 1 1111111111 1111111111 1 1111111 1 1111111

399 accagaggctgcagaggcgtgagatgcgctgccgacatcgtcggccagtg 448
187 CCCTGCCAAGCTGAAGGCCCCTGGAGGCGGCTGCAATGACGCCTGCACCG 236
11111111111111111111111111111111111111111111111111

449 ccctgccaagctgaaggcccctggaggcggctgcaat gacgcctgcaccg 498
237 TGTTTCAGACTAGTGAG 253
111111111 1 1 1 1 1 111

499 tgtttcagactagtgag 515

FIG. 38. DNA sequence of correct thaumatin C (rxn: 4060 #19 upper row) as
compared to the predicted sequence (lower row).
this nucleotide was not used in the fin al thaumatin sequence, this error was allowable and
the DNA was used for DNA construction. The sequences in figures 37 and 38 for
thaumatin B and C sequences, respectively, matched perfectly with the predjcted
sequences . In order to verify the identity of a correct clone of thaumatin D, it was
necessary to sequence in both ctirections, to confirm that the errors seen at the ends of the
sequence were actually artifacts from the sequencing. By comparing the results of
sequence a) and b) in figure 39, it was possible to confirm that reaction 3989 #26 had the
correct sequence with no true errors.

Combining thaumatin segments
Joining segments A&B and C&D
Due to the presence of both a Kpni and Spel enzyme recogrution sequences in the
multiple cloning site (MCS) of pUC 19, each pUC vector that contltined an insert was cut in
two places when it was digested with either Kpnl or Spel. As a result there were a number
of possible ligation products from the ligation of A & Band C & D. Many of them

76
a) sequencing with M13 forward primer
173 CCCCGTGTTTCAGACTAGTGAGTATTGCTGCACCACTGGCAAGTGCGGCC 124
I

111111111111111111111111111111111111111111111111

494 caccgtgtttcagactagtgagtattgctgcaccactggcaagtgcggcc 543
123 CTACCGAGTATAGCAGATTTTTTAAGAGACTGTGCCCTGACGCCTTTAGC 74
11111111111111111111111111111111111111111111111111

544 ctaccgagtatagcagattttttaagagactgtgccctgacgcctttagc 593
73 TATGTGCTGGACAAGCCTACCACCGTGACCTGCCCTGGCAGCAGCAACTA 24
11111111111111111111111111111111111111111111111111

594 tatgtgctggacaagcctaccaccgtgacctgccctggcagcagcaacta 643
23 TAGAGTGACCTTTTGCCGTACC 2
11111111111111111

1111

644 tagagtgaccttttgccctacc 665

b) sequencing with the Ml 3 reverse primer
1 TTTGTGCACCACTGGCAAGTGCGGCCCTACCGAGTATAGCAGATTTTTTA 50
II

1111111111111111111111111111111111111111111111

518 ttgctgcaccactggcaagtgcggccctaccgagtatagcagatttttta 567

51 AGAGACTGTGCCCTGACGCCTTTAGCTATGTGCTGGACAAGCCTACCACC 100
11111111111111111111111111111111111111111111111111

568 agagactgtgccctgacgcctttagctatgtgctggacaagcctaccacc 617
101 GTGACCTGCCCTGGCAGCAGCAACTATAGAGTGACCTTTTGCCCTACCGC 150
1111111111111111111111111111111111111111111111 1 111

618 gtgacctgccctggcagcagcaactatagagtgaccttttgccctaccgc 667
151 CTAGTAGGTCGACGCTGCG 169
1111111 1 11111111 1 11

668 ctagtaggtcgacgctgcg 686

FIG. 39. Sequencing of the correct thaumatin D (rxn: 3989#26).
in volved the re-ligation of pUC plasmid with itself as well as with the small regions cut
away from pUC multiple cloning site and the insert which would have resulted in ligation
products that did not contain any of the thaumatin fragments. The three possible ligation
events involving both thaumatin fragments are depicted in a linear fashion in fi gure 40,
although they could have been linear or circularized depending on the number of ligation
events that had occurred. The various pUC plasmids that contained the four di fferent
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thaumatin fragments were referred to as pUC I - 4 throughout figure 40 to distinguish them
from each another.
Because of the many possibilities for ligation, multiple PCR bands were predicted.
Therefore, the PCR product was fractionated on a non-denaturing 10% polyacrylamide gel
(PAGE) using a large sequencing gel apparatus. The apparatus was used to permit good
separat ion of the similar-sized bands. A large-volume PCR reaction was performed so that
enough DNA could be eluted from the PAGE to perform the next ligation. The ethidium
bromide-stained gel of the PCR reaction was photographed and is shown in figure 41.
Predominant bands appeared approximately at the predicted size of 323 bp for
thaumatin AB (lanes 3 through 7). ln lanes I0 through 15 a strong band at 383 was seen
for thaumatin CD.
Combining thaumatin AB and thaumatin CD
The ligation products of AB with CD were amplified by PCR, ligated into pUC,
and screened by double digestion with BamHI and EcoRI which, in a correct clone, would
liberate a band of approximately 680 bp. Those clones that had a diagnostic 680 bp band
were identified by arrows in figure 42. Several of these clones were sequenced by the
USU Biotechnology Laboratory.

Inserting flavor/sweetener genes into
p5'3'6cas construct
Screening ligation of the thaumatin gene
into p5 '3' Bcas
This section describes the ligation of thaumatin DNA sequence into the expression
vector, p5'3'Bcas. The brazzein DNA sequence was ligated into pS'Bcas and then the
3'Bcasein was ligated into the brazzein pS'Bcas. For the sake of brevity, the procedure for
doing this was not described because there was no significant difference in the protocol
other than the order in which DNA fragments were ligated into the plasmid backbone.
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Putative thaumatin-p5'3'Bcas clones were selected on the basis of the colony
hybridization autoradiograph (not shown). These clones were diagnosed by a double
digestion with Ppurnl and Sal!, which liberated the thaumatin sequence (680 bp) and
approximately 1.5 kb of the 3'13-casein sequence, thereby leaving behind the remaining 8.4
kb of the expression vector.
Those clones that were diagnosed by having the three predicted bands, as indicated
by arrows, on the gel seen in figure 43 were sequenced by the USU Biotechnology
Laboratory (not shown). The sequencing was done to confirm three things: I) that the
thaumatin sequence was still correct and no errors had occurred as a result of the PCR
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FIG. 40. Possible ligation events when joining thaumatin A & B and C & D.
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Lane I : I kb ladder size marker;
Lanes 3-7: AB PCR product;
Lanes 10-15: CD PCR product.

FIG. 42. Screening of thaumatin-pUC (gel# 1019).
Lanes 1 20 & 21 : I kb size marker;
Lanes 2-19 24: putative thaumatin-pUC clones.
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FIG. 43. Screening of thaumatin-p5'3'B-cas (gel #1049).
Lane I: A Hind III size marker;
Lanes 2-11: putative thaumatin-p5'3 'Bcas clones.
amplifications, 2) that the junction between thaumatin and the 5' region was in the correct
translational reading frame, and 3) that the junction between thaumatin and the 3' region
was in the correct translational reading frame. The sequencing data was analyzed to
confirm that the thaumatin expression vector was correct. The brazzein expression vector
was also sequenced and analysed prior to it being used for microinjection.
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Objective#2 Generation of transgenic lines to test the expression vector

Preparation of expression vector for
micro-injection
The DNA that comprised the expression vector (S ' B-casein region, synthetic
gene and 3 'B -casein region) was digested away from the plasmid backbone to prepare for
microinjection. This was accomplished by digesting the brazzein or thaumatin expression
vectors with the enzymes Aatii and Mlui. It was predicted that the following bands would
result from the reaction: 7.4 or 7.0 kb (desired band for thaumatin or brazzein expression
vector, respectively) and 3.1 kb (plasmid). The thaumatin expression vector exhibited the
predicted bands (figure 44) while the brazzein expression vector exhibited multiple bands
of various sizes. An example of the preparative I% Seaplaque GTG agarose gel used to
isolate the thaumatin expression vector was shown below in figure 44.
The 7.4 kb band that was to be excised from the gel was in close proximity to
uncut and partially cut DNA. The gel (figure 44) was run for a longer time (5-6 hours at

FIG. 44. Thaurnatin expression vector cut for microinjection (gel #1070).
Lane I: A. Hind ill size marker;
Lanes 3-7: thaumatin 3'5'Bcas cut with Aatii and M lui.
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75 V) than would normally be used, so that the bands would be well separated. In lane 5
of figure 44 , a faint band above the 7.4 kb band can be seen. As the 7.4 kb band was
exc ised from the gel, care was taken not to inadvertently include any uncut or partially cut
DNA.

When the brazzein expression vector was digested with the above-mentioned
enzymes, Aatll and Agel, additional bands were observed. To determine why these bands
were present, several diagnostic restriction enzyme reactions were performed. The
brazzein expression vector was cut separate ly with Aatii and Mlui. Both enzymes only
have one known enzyme site; therefore, the reaction should linearize the plasmid resulting
in one band at 10.1 kb. The Aatll digested DNA (figure 45 , lanes 3-6) yielded one band
but , the Mlui digested DNA (lanes 8- 11 ) resulted in two strong bands.
It was evident from the gel in figure 45 that there were two Mlui sites instead of
one. The expected enzyme sites of the brazzein expression vector were shown in figure
46. This schematic can be referenced to while examining the diagnostic gels to determine
that the newly identified Mlui site was not located in the 3'6-casein region . It was
determined that the additional enzyme recognition site was not in the 3'6-casein DNA
sequence by digesting the 3' region with Mlui. In figure 47, only one 2 kb-sized band
was seen in lanes 7 and 8, indicating that no additional Mlul site was present in the 3'6casein DNA.
To avoid working with the Mlul restriction digestion, another restriction enzyme
site, BamHI, at the 3' end of the 3' 6-casein gene (figure 46) was selected to excise the
expression vector away from the plasmid sequences, BamHI only cut once and the
reaction generated the predicted band of approximately 10.1 kb (lanes 2-5, figure 47).
Additional diagnostic restriction enzyme digestions were done to ensure the extra Mlul site
was not within the expression vector, and that all the other pertinent restriction enzyme
sites were as they should be, and would generate the correct size bands (data not shown).
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FIG. 45. Diagnostic agarose gel for brazzein expression vector using
restriction enzymes Aatll and Agel (gel# 974).
Lane I: AHindiii size marker;
Lanes 3-6: brazzein expression vector clones cut with Aatii;
Lanes 8-11: brazzein expression vector clones cut with Mlui.

Ppuml

Aatll

FIG. 46. Pertinent predicted restriction enzyme sites of brazzein expression
vector.
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FIG. 47. Diagnostic agarose gel for brazzein expression vector using
restriction enzymes BamHI and Mlul (gel# 977).
Lane I: 'A Hindiii size marker;
Lanes 2-5: Brazzein 3'5'13cas cut with BarnHI;
Lanes 7-9: 3'13-casein region cut with Mlui.
The brazzei n expression vector was digested first with Aatii and then with BamHI
to prepare the vector for microinjection. This reaction yielded a band of approximately
6.75 kb. An example of such a preparative gel (Seaplaque GTG agarose) to isolate the
brazzein expression vector for microinjection is shown in figure 48. The 6.7 kb fragment
that was excised for microinjection was indicated by an arrow. The upper band was uncut
DNA that was not excised from the gel.

Screening of potential transgenic animals
The ethidium bromide-stained agarose gel used for the Southern blot analysis had
the fo llowing DNAs loaded in the indicated lanes (figures 49 & 50).
The positive control carrying an equivalent of about 10 copies/cell had one band on
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FIG. 48. Brazzein expression vector cut for rrticroinjection (gel# 984).
Lane I : A. Hindill size marker;
Lanes 3-5: brazzein 3'5 ' Bcas cut with Aatii and BarnHI.

FIG. 49. Ethidium brorrtide stained agarose gel
prepared for murine genorrtic Southern blot (gel# 1164).
Lanes I & 14: A. Hindill size marker;
Lanes 2 & 20: linearized thaumatin plasrrtid positive control:
10 copies and I copy respectively;
Lanes 3-13. 15-19 & 21-26: approximately 10 J.l.g of putative transgenic
murine DNA per lane cut with Hinfl.
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FIG. 50. Autoradiograph of murine genomic Southern blot
(gel# 1164). Positive bands were identified using a probe of 32 P
labeled thaumatin gene. Positive bands are seen in:
Lane 2: positive control;
Lane 4: mouse #77 ;
Lane 23: mouse #94;
Lane 26: mouse #97.
the Southern blot hybridized filter (lane 2, figure 50). Some of the lanes containing
putative transgenic murine genomic DNA also revealed signal bands, which indicated that
these mice possessed DNA homologous to the thaumatin trans gene.
To verify these results, another hybridization blot was done and the results
obtained (data not shown). The second blot was done using alkaline transfer (3) instead
of Southern transfer, to try and improve the quality of the hybridization. The different
transfer protocol showed no improvement. As in the autoradiograph shown in figure 50,
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the bands were not discrete and accurate Jane identification was difficult. In future
reactions, fresh Denhardt's solution was made. Freshly made Denhardt' s removed the
problem of diffuse bands as is evident in figure 54 using goat genomic DNA.
Tail biopsies of founder (FO) and first-generation progeny (Fl) mice were
screened for the trans gene (figures 51 & 52) to determine if the trans gene was inheritable.
The only positive control that was visible on the autoradiograph after exposure for 6
weeks at 80°C was the 300 copy equivalent (concentration of positive controls was
calculated so as to approximate copy numbers to determine what levels of copy number

could be detected in murine samples). This indicated that the sensitivity of the probe was
insufficient to detect all transgenic mice with this particular gel. However, two putative

FIG. 51. Agarose gel prepared for FO and Fl murine genomic Southern blot
(gel# 1126).
Lane 1: I kb ladder size marker;
Lane 2: 5.5 pg positive control (thaumatin plasmid cut with Hinfi)- 3 copy
equivalent;
Lanes 4-9: 10 1-!g of putative transgenic murine DNA per Jane cut with Hinfl;
Lane II : 55 pg positive control- 30 copy equivalent;
Lane 13: 550 pg positive control- 300 copy equivalent;
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FIG. 52. Autoradiograph of FO and F 1 murine genomic Southern
blot (gel# 1126).
F l transgenic mouse samples had bands. They were mouse number 165, which was the
offspring of mouse number 77 (fi gures 51 & 52), and 140, a founder mouse.
Although it was not part of thi s candidate's objectives to use goats to test the
expression vector, caprine embryos were inj ected with the thaumatin expression vector.
Fetal tissue was obtained from the umbilicus (25) at birth and screened for the trans gene.
In order to have a replica of the data, the lower section of the gel (figure 53)
contained the same samples as were loaded on the upper portion of gel. The only
difference between the lower and upper portions of the gel being the order in which the
samples were loaded onto the gel.
The positive controls were evident in lanes 2 and 4 of figure 54 on a film that was
developed after 3 days. Goat #28 in lane 13 had a strong band that lined up with the lower
band of the thaumatin plasmid con trol in lane 2.
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FIG. 53. Agarose gel prepared for genomic caprine Southern blot
(gel# 1218).
Lane 1: I kb ladder size marker;
Lane 2: 1000 copy equivalent thaumatin p3'5'Bcas cut with Hinfl;
Lane 4: 330 copy equivalent thaumatin-pUC cut with Hinfl;
Lane 6: negative control: 10 J..Lg non-transgenic goat DNA cut with Hinfl;
Lanes 7 8 & 10-28: 10 J..Lg putative transgenic goat DNA cut with Hinfl.

1"2.1!

FIG. 54. Autoradiograph of genomic caprine Southern blot after
3-dal,' exposure (gel # 1218). Positive bands were identified using a probe
of 3 P labeled thaumatin gene.
Lane 1: I kb ladder size marker;
Lane 2: 1000 copy equivalent thaumatin p3'5'Bcas cut with Hinfl;
Lane 4: 330 copy equivalent thaumatin-pUC cut with Hinfl;
Lane 6: negative control: 10 J..Lg non-transgenic goat DNA cut with Hinfl;
Lanes 7,8 & 10-28: 10 J..Lg putative transgenic goat DNA cut with Hinfl.

90

FIG. 55. Autoradiograph of genomic caprine Southern blot after
6-week exr,osure (gel# 1218). Positive bands were identified using a
probe of 3 P labeled thaumatin gene.
Lane 14: 1 kb ladder size marker;
Lane 15: 1000 copy equivalent thaumatin p3'5'Bcas cut with Hinfl;
Lane 16: 330 copy equivalent thaumatin-pUC cut with Hinfl;
Lane 17: negative control : 10 !lg non-transgenic goat DNA cut with Hinfl;
Lanes 18 19 21,23-24 & 26: JO !lg putative transgenic goat DNA cut with Hinfl.
The overexposed autoradiograph at 6 weeks demonstrated that the positive band of
number 28 lined up with the lower band seen on the positive controls (demarcated by an
arrow, figure 55). In addition , there was no background seen in the lanes that contained
the other putative transgenic goat samples (lanes 18,19,21,23-24) or the negative control
(lane 17). The extraneous bands to the left of lane 15 were residual radiographic signals
from the lane containing the 1 kb ladder DNA size marker that was cut away from the
filter.
Objective 3: Detection of protein in the milk of the transgenic mice
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ELISA assays were developed to detect the thaumatin or brazzein proteins (figure
15). In order to optimize the reaction for the various components, multiple checker-board
assays were done. The optimal amount of goat and rabbit antibody was determined by
using log 10 serial dilutions of the antibody-containing serum and comparing the results at
different concentrations. The first antibody (goat) was used at three dilutions between l x
10·' to I x

w·' in the following two figures (figures 56 and 57), which shows the results of

the brazzein assay. The second antibody (rabbit), directed against brazzein, was used at I
x 10"2 dilution throughout the assay. The difference between the two figures was that in
figure 56 the antigen was diluted in phosphate-buffered saline (PBS) (3), while in figure 57
the antigen was diluted in bovine milk.
In figure 56, the absorbance reading at 450 nm decreased in a linear fashion
corresponding to the decreasing antigen concentration. When the milk was used as a
diluent instead of PBS, however, no linearity was observed (figure 57). The reason for
inhibition was not known.
The thaumatin assay was done using the same parameters as with the brazzein,
except that antisera specific

forth~

crude thaumatin plant protein were used for the standard

curve. The same interference with linearity observed with the brazzein assay was also
observed with the thaumatin assay when milk was used as the diluent instead of PBS
(figures 59 & 58, respectively).
It was evident that transgenic proteins secreted into the milk could not be identified
using antibodies without further development of the ELISA. As another method for
identifying the brazzein or thaumatin proteins in mouse mi lk, a mi lk sample from a
transgenic female mouse (#77) was analyzed by capillary electrophoresis. Controls of
crude thaumatin plant protein were electrophoresed to determine the electrophoretic location
of thaumatin when compared to the normal mouse mi lk proteins. The main peak of cmde
thaumatin plant protein (figure 60, top panel) was compared with the proteins from the
non transgenic mouse milk control (figure 60, middle panel) and a sample containing an
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FIG. 56. ELISA with brazzein multiple antigenic peptide diluted in PBS . The optical
density (00) is shown on they-axis against the concentrations of antigen added to the
wells on the x-axis. Three different concentrations of goat capture antibody were used.
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FIG. 60. Capillary electrophoresis of normal mouse milk spiked with crude plant
thaumatin. The main peak that is present in the crude thaumatin is not present in the mouse
milk control and is seen as a lower peak in the spiked mouse milk. A line has been drawn
through these areas to indicate them more clearly. Portions of the upper two panels are
shown in fi gure 61 and 62.
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equal (v/v) mixture of thaumatin and mouse milk (figure 60, bottom panel). The thaumatin
peak was to the right of two mouse milk protein peaks. This indicated the region in which
one could expect transgenic thaumatin to appear in transgenic mouse milk, although there
could be slight variation due to differences between glycosylation of the protein in the
mammary gland and glycosylation in the wild-type plant protein.
In the lower panel of figure 60 that contained mouse milk with added thaumatin
plant protein, the profile of the mouse milk proteins was altered. The intensity and location
of the various endogenous milk proteins were altered as a result of the added crude plant
thaumatin protein. This could be due to the possible existence of contaminating proteinase
activity in the cmde thaumatin preparation from plants that would alter the normal mouse
milk profile. Contaminating proteases wou ld not be present in the transgenic protein,
however.
Based on the results from figure 60, the transgenic thaumatin protein was expected
to be located to the right of a milk-protein doublet. Enlargements were made of two of the
graphs seen in figure 60 for the purpose of comparison with the transgenic mouse samples
(figures 61 & 62). Milk samples from a previously identified transgenic thaumatin mouse
#77 (figure 63), and samples from three non-thaumatin transgenic mice, were assayed.
The data have been represented in figures 63 through 66 as computer enlargements of the
doublet region where exogenous thaumatin was normally located. An additional peak
(arrow) at this location was identified in the transgenic mouse #77 (figure 63) , but it was
not seen in the three other non-thaumatin transgenic mice (figures 64-66). The absence of a
peak in the same region in the non-thaumatin transgenic mouse samples was indicated by
an arrow corresponding to the position of the extra peak seen in the transgenic mouse
(figures 64-66).
Goat milk cannot be analyzed at this stage because the kids need to mature and give
birth before being able to obtain milk from them.
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FIG. 61 . Capi llary electrophoresis of mouse milk control. The fraction area identified as
containing the thaumatin spike has been enlarged. Note the absence of peak (arrow) at 1616.5 minutes as compared to the large peak seen in thi s region in figure 62.
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FIG. 62. Cap ill ary elec trophores is of crude thaumatin protein. The peak seen with
thaumatin protein appears in the fraction region of 16- 16.5 min.
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FIG. 63. Capillary electrophoresis of milk from mouse #77.
in the region of 16-16.5 min (arrow) .

An additional peak is seen
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FIG. 64. Capi llary electrophoresis of nontransgenic mouse #il litter mate milk.
No additional peak is seen in the region of 16-16.5 min.
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FIG. 65. Capillary electrophoresis of nontransgenic mouse # 19 litter mate milk.
No additional peak is seen in the region of 16- 16. 5 min.
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FIG. 66. Capillary electrophoresis of milk from a nontransgenic mouse.
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DISCUSSION
Objective l: Construction of expression vector

p-casei n

gene

The regulatory elements of the protein expression vectors used in this research
con sisted of 3.8 kb of the 5' bovine beta-casein and 2.2 kb of the 3' bovine beta-casein
gene regulatory sequence. This was predicted to be an effective promoter based on the
beta-casein gene being one of the most predominant milk proteins at an amount of 9 giL
(28 % of total milk protein). The 5' and 3' sequences included three introns. The inclusion
of introns in transgenic expression vectors was shown to markedly increase the
transcription efficiency (22) . Varying sizes of regulatory sequences from the bovine betacasein gene have been successfully used in expression vectors for a number of different
proteins that have differing post-translational modifications (37). We hypothesize that
using a larger regulatory region than has been previously used containing multiple introns
and non-coding exons increases the probability of a functional protein being secreted at a
concentration suitable for commercial production: Consequently, the use of bovine betacasein regulatory sequences for this study was justified.
Cloning of the expression vector
Several novel cloning techniques were used in the making of the expression vector.
These approaches worked well and should have applications for cloning a variety of genes
into plasmids quickly and efficiently. Firstly, PCR products were treated with proteinase
K to digest interfering substances, presumably so that the PCR products could be c loned
more effecti vely. Secondly, T4 polymerase and polynucleotide kinase were used together
in the blunt end reaction of the PCR products in preparation for ligation into pUC-Smai.
Additionally, our plasmid was found to have low transformation efficiency when subjected
to agarose gel purification using beta-argarase digestion or dialysis. This was possibly due
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to traces of argarose that were remained with the DNA. To bypass this problem, no gel
purification was done. The ligation was done directly after restriction enzyme digestion
and the transformants were screened using colony hybridization (figure 26).

Synthesis of long oligonucleotides
In order to have the gene containing common codons that would facilitate
mammaliam protein expression, synthetic genes had to be made. Synthesis of long
oligonucleotides is not frequently done due to high error rates that can occur when making
long oligonucleotides of more than 60 bases. Therefore, thaumatin and brazzein were
synthesized by making several oligonucleotides, ranging in size from 50 to I 00 bases, that
could be assembled together into the complete gene. This permitted the generation of DNA
strands 220 and 660 bp in length. Effective cloning of the long synthetic gene for
thaumatin (660 bp) was accomplished by designing overlapping oligonucleotides that could
be hybridized together to make separate fragments of the gene. These fragments were then
ligated together using restriction enzyme sites that were designed into the ends of the
fragments. The restriction enzyme sites were designed so that when oligonucleotides were
ligated together, the complete gene sequence would be in the correct translational reading
frame (figure 8). A non-palindromic enzyme site was selected for the middle of the gene to
minimize the formation of self-ligation between oligonucleotides. Ligation was done with
either PCR product that had been isolated from a PAGE or directly on PCR product. No
transformation problems were seen with the PAGE purified sequences that had been ligated
into pUC.
Objective 2: Generation of transgenic lines to test the expression vector

Identification of transgenic animals
Probes from the vector DNAs were used to identify transgenic mice and a goat.
The thaumatin transgene was identified in founder mice #77 (female) and #140 (male) and
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has been shown to be inheritable by identification of offspring from mouse #77 . The
studies on brazzein mice were stopped because an error in the original brazzein sequence
published in the patent was synthesized and would have produced changes in the amino
acid sequence. These errors would have probably yielded a nonfunctional protein.
Therefore, for the sake of time and money, further investigation was suspended on the
brazzein work. However, the brazzein gene sequence error is currently being corrected.
Objective 3: Detection of protein in the milk of the transgenic mice

Identification of thaumatin protein
in mouse milk
The thaumatin protein has tentatively been identified in mouse milk from transgenic
mouse #77 . The protein was detected as an additional peak when compared to
non transgenic mouse milk samples using capillary electrophoresis. This could be due to
the possible existence of contaminating proteinase activity in the crude thaumatin
preparation from plants that would alter the normal mouse mi lk profile. Contaminating
proteases would not be present in the transgenic protein, however.
It is anticipated that the protein wi ll be produced at a yield of approximately 2-3g!L.
As stated in the Literature Review, all indications are that the thaumatin protein will be
expressed as a functionally sweet protein. However, this is not known at this point. This
wi ll be tested using non-human primate taste tests of thaumatin milk compared to negative
controls of non-transgenic milk from litter mates and milk from the transgenic animal that
has been deactivated by heat treatment. Thaumatin has an extremely sweet taste and even at
low levels its presence should be evident. There are several reasons why functional protein
would not be secreted. The signal peptide could be incorrectly or poorly recogni zed,
resulting in little or no prote in present in the milk. The protein could also be incorrectly
folded in a mammalian system, such that it is not functi onally sweet. Addition ally, the
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physiological environment provided by the milk could result in the protein not being
functional , although I believe that this is unlikely.
From an economic standpoint, if the protein is not functionally sweet, because of
the relatively low costs of mammary gland production as compared to the natural supply
and some of the other methodologies used, it could still be cost effective to produce the
protein which is not functional and then chemically modify it.

Immunoassay to detect protein
An ELISA has been designed to detect and quantify the thaumatin and brazzein
proteins. It was determined during development of the assay that the presence of milk
interfered with the specificity or linearity of the assay. It is hypothesized that the milk
contains inhibitory substances that block the epitope on the goat antibody, thereby
preventing antigen recognition. Alternatively, there could be other antibodies present in the
serum that are binding the milk proteins. This would result in a hi gh background level ,
thereby preventing the detection of any significant color change resulting from the varying
thaumatin protein concentrations. As evidence of thi s, when the assay was performed with
antigen diluted in PBS instead of milk, a linear relationship between absorbance and
antigen concentration was seen. While there is a linear relationship, diluting in PBS is only
effective for the controls. Because the proteins are produced in milk, one of two things
needs to be done. The antigen (thaumatin protein) needs to be isolated from the milk prior
to performing the assay. Alternatively, the antibody could be purified by affinity
chromatography. By binding purified antigen to chromatography beads and passing the
serum over the matrix , the antibody specific to thaumatin and brazzein would be retained in
the colomn and could then be eluted.
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CONCLUSION
This project has resulted in:
l. Successful cloning of an expression vector that has tentatively been shown to produce

the thaumatin protein in the milk of genetically engineered animals.
2. Development of a novel technique to produce long error-free synthetic genes.
3. Development of an ELISA that can detect the thaumatin and brazzein proteins in a
concentration-dependent manner.
In order to achieve the long-term goal of using these expression vectors to produce and
detect the proteins in the milk of dairy animals, the following work remains to be done:
1. Characterize the stability of the transgene from one generation to the next. This will be
done by continuing to screen transgenic mice from the founder animals that have been
shown to carry the trans genes. The relative copy numbers of the trans genes over
several generations will then be compared as an indicator of stabili ty of the gene at the
integration site peculiar to each transgenic line.
2. Mutate the incorrect brazzein expression vector into the correct sequence to yield
functiona l protein expression. Insert the correct gene sequence into the expression
vector using the same protocol described in the Methods section. Generate transgenic
mice to test the brazzein expression vector and characterize the transgene and protein as
described for thaumatin.
3. Optimize the protocol for obtaining and storing mouse milk so that sufficient quantities
can be obtained from each mouse to screen for the protein. There are several stages at
which this process could potentially be enhanced. The oxytocin levels and time
between injection and initiation of the milking should be optimized. In addition, the
homemade mouse milking pump could possibly be modified to get better suction.
Lastly, when fro ze n for long periods of time, the mouse milk seems to become very
thick and difficult to work with for the ELISA. Perhaps the milk shou ld either be
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assayed soon after it is obtained with on ly refrigeration at 4 C or a medium cou ld be
obtained to store the milk in. Because mouse milk is injtially thicker and more
concentrated than milk obtained from dairy animals, I do not anticipate this being a
problem encountered with large-scale protein production.
4 . Develop a protocol for purifying transgenic protein away from milk so that the protein
can be characterized biochemically.
5. Obtain milk from goat# 28 and screen for the protein by ELISA, capi llary
electrophoresis, and Western blot to validate the presence of the thaumatin.
6. Once the protein presence has been confirmed, perform physiological taste studies and
biochemical studies to show that the protein is secreted and folded such that it is
functional.
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